Uniform Medical Plan coverage limits

*Updates effective 10/1/2019*

The benefit coverage limits listed below apply to these UMP plans:
- Uniform Medical Plan (UMP) Classic (PEBB)
- UMP Consumer-Directed Health Plan (UMP CDHP) (PEBB)
- UMP Plus–Puget Sound High Value Network (UMP Plus–PSHVN) (PEBB)
- UMP Plus–UW Medicine Accountable Care Network (UMP Plus–UW Medicine ACN) (PEBB)
- UMP Achieve 1 (SEBB)
- UMP Achieve 2 (SEBB)
- UMP High Deductible Plan (SEBB)
- UMP Plus–Puget Sound High Value Network (UMP Plus–PSHVN) (SEBB)
- UMP Plus–UW Medicine Accountable Care Network (UMP Plus–UW Medicine ACN) (SEBB)

Some services listed under these benefits have coverage limits. These limits are either determined by a Health Technology Clinical Committee (HTCC) decision or a Regence BlueShield medical policy. *The table below does not include every limit or exclusion under this benefit. For more details, refer to your plan’s Certificate of Coverage.*

Uniform Medical Plan Pre-authorization List

The Uniform Medical Plan (UMP) Pre-authorization List includes services and supplies that require pre-authorization or notification for UMP members.

Click to view important upcoming pre-authorization changes:

- **Pharmacy: Infusion Drug Site of Care** – effective January 1, 2020
- **Physical Medicine**
  - Physical therapy, speech therapy, occupational therapy (PT/OT/ST) – effective March 1, 2020
    - PEBB: UMP Classic, UMP CDHP and UMP Plus – Limit 60 annual visits
    - SEBB: UMP Achieve 1, UMP Achieve 2, UMP High Deductible – Limit 80 annual visits
    - SEBB: UMP Plus – Limit 60 annual visits
  - Pain management – effective January 1, 2020
  - Joint management – effective January 1, 2020
  - Spine – effective January 1, 2020
- **Radiology** – effective January 1, 2020
- **Sleep Medicine** – effective January 1, 2020

These criteria do not imply or guarantee approval. Please check with your plan to ensure coverage.

Preauthorization requirements are only valid for the month published. They may have changed from previous months and may change in future months.
## Durable Medical Equipment

<table>
<thead>
<tr>
<th>These services or supplies have coverage limits</th>
<th>The rules or policies that define the coverage limits</th>
<th>Limit applies to these codes (chosen by your provider to bill for services)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone Growth Stimulation</td>
<td>HTCC decision</td>
<td>• 20974, 20975, 20979, E0747, E0748, E0749, E0760</td>
</tr>
<tr>
<td>Continuous Glucose Monitoring</td>
<td>HTCC decision</td>
<td>• A9277, A9278, K0554, S1030, S1031</td>
</tr>
<tr>
<td>Implantable Drug Delivery System</td>
<td>HTCC decision</td>
<td>• C1772, C1889, C1891, C2626, E0782, E0783, E0785, E0786</td>
</tr>
<tr>
<td>Insulin Infusion Pumps and Artificial Pancreas Device System (APDS)</td>
<td>Regence Medical Policy DME77</td>
<td>• Effective November 1, 2019: E0784</td>
</tr>
<tr>
<td>Microprocessor-Controlled Lower Limb Prosthetics</td>
<td>HTCC decision</td>
<td>• L5856, L5857, L5858 Use <a href="#">Regence Medical Policy DME81</a> in addition to the HTCC to review requests regarding &quot;functional level 2&quot; and &quot;experienced user exceptions&quot;.</td>
</tr>
<tr>
<td>Noninvasive Ventilators in the Home Setting</td>
<td>Regence Medical Policy DME87</td>
<td>• Effective November 1, 2019: E0466</td>
</tr>
<tr>
<td>Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Conditions</td>
<td>Regence Medical Policy DME45</td>
<td>• E0481, E0483</td>
</tr>
<tr>
<td>Power Wheelchairs: Group 3</td>
<td>Regence Medical Policy DME37</td>
<td>• Effective November 1, 2019: K0848, K0849, K0850, K0851, K0852,</td>
</tr>
</tbody>
</table>

October 1, 2019

These criteria do not imply or guarantee approval. Please check with your plan to ensure coverage. Preauthorization requirements are only valid for the month published. They may have changed from previous months and may change in future months.
<table>
<thead>
<tr>
<th>Programmable Pneumatic Compression Pumps</th>
<th>Regence Medical Policy DME78</th>
<th>E0652</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stents, Drug Coated or Drug-Eluting (DES)</td>
<td>HTCC decision</td>
<td>Refer to Cardiac Stenting in the Surgery section.</td>
</tr>
</tbody>
</table>
NOTE: This policy has been revised. The revised policy will be effective November 1, 2019. To view the revised policy, click here.

Artificial Pancreas Device System (APDS)

Effective: November 1, 2018

Next Review: October 2019
Last Review: October 2018

IMPORTANT REMINDER

Medical Policies are developed to provide guidance for members and providers regarding coverage in accordance with contract terms. Benefit determinations are based in all cases on the applicable contract language. To the extent there may be any conflict between the Medical Policy and contract language, the contract language takes precedence.

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these services.

DESCRIPTION

Artificial Pancreas Device Systems (APDS), is a closed-loop system which monitors glucose levels and automatically adjusts the delivery of insulin to help achieve tight glucose control.

MEDICAL POLICY CRITERIA

Note: This policy is not intended to address insulin pumps that include a basal insulin delivery algorithm and/or a low glucose or low threshold suspend feature, which may be considered medically necessary.

Use of an artificial pancreas device system, is considered investigational.

NOTE: A summary of the supporting rationale for the policy criteria is at the end of the policy.

CROSS REFERENCES

None
Maintenance of a target blood glucose and target glycated hemoglobin (HgA1c < 7%), a marker which is used as a proxy for average blood glucose, is now considered standard of care for diabetic patients. Also known as tight diabetic control, this strategy is intended to prevent severe hypoglycemic events and lower the risk of cardiovascular disease mortality associated with uncontrolled glycemia.[1] The strategy involves frequent home blood glucose checks (fingersticks) several times each day (i.e., before meals and at bedtime). Measurement of blood glucose at such specific points in time may not reveal trends in blood glucose, particularly those associated with nighttime sleep.

Artificial pancreas or artificial pancreas device systems (APDSs) are currently under development by device manufacturers as an adjunct to traditional self blood glucose monitoring to help achieve tight glucose control. According to the U.S. Food and Drug Administration (FDA)[2], an artificial pancreas device system is sometimes referred to as a “closed-loop” system or an ‘autonomous system for glycemic control.’ “In the future, APDSs will not only monitor glucose levels in the body but also automatically adjust the delivery of insulin to reduce high blood glucose levels (hyperglycemia) and minimize the incidence of low blood glucose (hypoglycemia) with little or no input from the patient.” According to the FDA, an artificial pancreas device systems consists of 3 components that work together to provide an autonomous system for glycemic control:

- Continuous glucose monitor (CGM) device which may be calibrated based on blood glucose measures.
- Control algorithm-software which calculates dosing instructions sent to the infusion pump.
- Infusion pump-the pump adjusts the insulin delivery.

Development of the APDS is occurring in stages. One stage uses technology associated with artificial pancreas development and has a “low glucose suspend (LGS)” feature included with an insulin pump. The LGS feature is designed to suspend insulin delivery when plasma glucose levels fall below a pre-specified threshold. The LGS feature is not considered an artificial pancreas as it does not autocorrect for highs and lows with minimal patient involvement, also known as a closed-loop system. The LGS is, however, a step toward the development of APDSs.

There are several hybrid or LGS systems that are FDA approved. One such system is the MiniMed® 670G System with SmartGuard™ by Medtronic© which received PMA approval from the FDA.[3] This hybrid closed-loop system uses a CGM to automatically adjust basal insulin pump delivery to a target blood glucose of 120mg/dl. While it does automatically increase or decrease the basal insulin in response to CGM readings using algorithm software, it is not a completely closed-loop system, and the user is still required to provide input for insulin boluses after meals. Therefore, it does not meet the definition of an APDS.

The next stage will have all the components working together (insulin pump, CGM, and control algorithm), with little or no user input. The user will not have to check blood sugar or inject insulin manually. According to the FDA, the control algorithm can be in a computer, cellular phone or the insulin pump.[2] The FDA does not require the control algorithm be integrated into the insulin pump. There are APDSs undergoing clinical trials that include algorithms to control the insulin.[4,5]
REGULATORY STATUS

Currently there are no closed-loop/autonomous systems for glycemic control APDSs that can truly replace the function of a pancreas approved by the U.S. Food and Drug Administration (FDA) for commercial use.

EVIDENCE SUMMARY

The key clinical outcomes regarding the clinical utility of artificial pancreas device systems (APDSs) relate to their ability to improve the morbidity/mortality associated with clinically significant, severe, and acute hypoglycemia or hyperglycemic events.

Randomized controlled trials have evaluated insulin pumps with various functionalities including a low glucose suspend (LGS) feature which is thought to be an initial step toward the development of an automated, closed-loop artificial APDS. However, these devices are not true “closed-loop” systems and do not replace the function of a pancreas; therefore, are not addressed by this policy.

There are additional studies evaluating APDSs that include algorithms used in conjunction with an insulin pump and CGM, but clinical trials are ongoing and no true APDSs are FDA approved.

PRACTICE GUIDELINE SUMMARY

There are no evidence-based clinical practice guidelines that recommend the use of an artificial pancreas for the management of diabetes.

SUMMARY

Currently, there are no artificial pancreas device systems (APDS) that truly replace the function of a pancreas that have been approved by the U.S Food and Drug Administration (FDA). Therefore, APDSs are considered investigational for people living with diabetes.

REFERENCES


<table>
<thead>
<tr>
<th>CODES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Codes</td>
</tr>
<tr>
<td>-------</td>
</tr>
<tr>
<td>CPT</td>
</tr>
</tbody>
</table>

These criteria do not imply or guarantee approval. Please check with your plan to ensure coverage. Preauthorization requirements are only valid for the month published. They may have changed from previous months and may change in future months.
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>S1035</td>
<td>Sensor; Invasive (eg, Subcutaneous), Disposable, For Use With Artificial Pancreas Device System</td>
</tr>
<tr>
<td>S1036</td>
<td>Transmitter; External, For Use With Artificial Pancreas Device System</td>
</tr>
<tr>
<td>S1037</td>
<td>Receiver (Monitor); External, For Use With Artificial Pancreas Device System</td>
</tr>
</tbody>
</table>

**Date of Origin:** September 2000

These criteria do not imply or guarantee approval. Please check with your plan to ensure coverage.
Preauthorization requirements are only valid for the month published. They may have changed from previous months and may change in future months.
**Powered Knee Prosthesis, Powered Ankle-Foot Prosthesis, Microprocessor-Controlled Ankle-Foot Prosthesis, and Microprocessor-Controlled Knee Prosthesis**

**Effective:** July 1, 2019

**Next Review:** September 2019  
**Last Review:** June 2019

---

**IMPORTANT REMINDER**

Medical Policies are developed to provide guidance for members and providers regarding coverage in accordance with contract terms. Benefit determinations are based in all cases on the applicable contract language. To the extent there may be any conflict between the Medical Policy and contract language, the contract language takes precedence.

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these services.

---

**DESCRIPTION**

These computerized prostheses use feedback from sensors to adjust joint movement on a real-time as-needed basis.

---

**MEDICAL POLICY CRITERIA**

I. **Microprocessor-controlled knee may be considered medically necessary** in amputees when all of the following criteria are met (A – E):

   A. At least one of the following criteria are met:

      1. Demonstrated need for ambulation at variable rates or for long distances such that the patient would benefit from a device that may reduce energy consumption. (Use of the limb only in the home and/or for basic community ambulation does not establish medical necessity of the computerized limb over standard limb applications); or

      2. Demonstrated daily activities or job tasks that do not permit full focus of concentration on knee control and stability, including but not limited to ambulation on uneven terrain, curbs, ramps, regular use on stairs or repetitive
lifting and/or carrying. (Use of the limb for limited stair climbing in the home or employment environment does not establish medical necessity of the computerized limb over standard prosthetic application).

B. All of the following criteria must be met to demonstrate adequate physical ability:
   1. Adequate cardiovascular and pulmonary reserve for ambulation at faster than normal walking speed; and
   2. Adequate stride strength and balance to activate the knee unit; and
   3. Classified as one of the following Medicare Functional Levels:
      a. Select Level K2—Patients capable of limited community ambulation, but only if improved stability in stance permits increased independence, decreased risk of falls, and potential to advance to a less restrictive walking device. The microprocessor is required to enable fine-tuning and adjustment of the hydraulic mechanism to accommodate the unique motor skills and demands of the functional level K2 ambulator; or
      b. Level K3—Patients who have the ability or potential for ambulation with variable cadence. Typical of the community ambulator who has the ability to traverse most environmental barriers and may have vocational, therapeutic, or exercise activity that demands prosthetic utilization beyond simple locomotion; or
      c. Level K4—Patients who have the ability or potential for prosthetic ambulation that exceeds basic ambulation skills, exhibiting high impact, stress, or energy levels. Typical of the prosthetic demands of the child, active adult, or athlete.

C. Adequate cognitive ability to master use and care requirements for the technology; and
D. Patients with amputation from hemi-pelvectomy through knee-disarticulation level including bilateral lower extremity; and
E. All of the following criteria must also be met:
   1. Stable or absent wound; and
   2. The request is for either a microprocessor-controlled knee or a non-microprocessor-controlled mechanical prosthesis but not both for a single knee; and
   3. Adequate socket fitting with the potential to return to active lifestyle.

II. A microprocessor-controlled knee is considered not medically necessary when Criterion I. is not met or when any of the following apply:
   A. Medicare Functional Levels K0, K1, and the subset of K2 patients capable of limited community ambulation who do not have the cardiovascular reserve, strength, and balance to improve stability in stance to permit increased independence, decreased risk of falls and potential to advance to a less restrictive walking device
   B. When the primary benefit is to allow the patient to perform leisure or recreational activities
C. Inability to tolerate the weight of the prosthesis
D. Significant hip flexion contracture (over 20 degrees)
E. Patient falls outside of recommended weight or height guidelines of manufacturer

III. A powered knee or ankle-foot or a microprocessor-controlled ankle-foot is considered investigational.

NOTE: A summary of the supporting rationale for the policy criteria is at the end of the policy.

LIST OF INFORMATION NEEDED FOR REVIEW

It is critical that the list of information below is submitted for review to determine if the policy criteria are met. If any of these items are not submitted, it could impact our review and decision outcome.

- History and Physical/Chart Notes
- Documentation of need at variable rates or for long distance ambulation from a device that reduces energy consumption
- Documentation of specific ADLS including job tasks that call do not permit full focus of concentration on knee control and stability
- Documentation of adequate ability to ambulate faster than normal walking speed including cardiovascular/pulmonary reserve, stride length, balance, Medicare Functional Level, and cognitive ability
- Type of amputation
- Wound status if applicable

CROSS REFERENCES

1. Myoelectric Prosthetic Components for the Upper Limb, DME, Policy No. 80

BACKGROUND

MICROPROCESSOR-CONTROLLED PROSTHETIC KNEES

Microprocessor-controlled prosthetic knees have been developed, including the Intelligent Prosthesis (IP) (Blatchford, England), the Adaptive (Endolite, England), the Rheo Knee® (Össur, Iceland), the C-Leg®, Genium™ Bionic Prosthetic System, and the X2 and X3 prostheses (Otto Bock Orthopedic Industry, Minneapolis, MN), and Seattle Power Knees (3 models include Single Axis, 4-bar and Fusion, from Seattle Systems). These devices are equipped with a sensor that detects when the knee is in full extension and adjusts the swing phase automatically, permitting a more natural walking pattern of varying speeds. For example, the prosthetist can specify several different optimal adjustments that the computer later selects and applies according to the pace of ambulation. In addition, these devices (with the exception of the IP) use microprocessor control in both the swing and stance phases of gait. (The C-Leg Compact provides only stance control). By improving stance control, they may provide increased safety, stability, and function. For example, the sensors are designed to recognize a stumble and stiffen the knee, thus avoiding a fall. Other potential benefits of microprocessor-controlled knee prostheses are improved ability to navigate stairs, slopes, and uneven terrain and reduction in energy expenditure and concentration required for ambulation.
The C-Leg was cleared for marketing in 1999 through the 510(k) process of the U.S. Food and Drug Administration (FDA; K991590). Next-generation devices such as the Genium Bionic Prosthetic system and the X2 and X3 prostheses utilize additional environmental input (e.g., gyroscope and accelerometer) and more sophisticated processing that is intended to create more natural movement. One improvement in function is step-over-step stair and ramp ascent. They also allow the user to walk and run forward and backward. The X3 is a more rugged version of the X2 that can be used, for example, in water, sand, and mud. The X2 and X3 were developed by Otto Bock as part of the Military Amputee Research Program.

MICROPROCESSOR-CONTROLLED ANKLE-FOOT PROSTHESES

Microprocessor-controlled ankle-foot prostheses are being developed for transtibial amputees. These include the Proprio Foot® (Össur), the iPED (developed by Martin Bionics and licensed to College Park Industries), and the Elan Foot (Endolite). With sensors in the feet that determine the direction and speed of the foot’s movement, a microprocessor controls the flexion angle of the ankle, allowing the foot to lift during the swing phase and potentially adjust to changes in force, speed, and terrain during the step phase. The intent of the technology is to make ambulation more efficient and prevent falls in patients ranging from the young active amputee to the elderly diabetic patient. The Proprio Foot™ and Elan Foot are microprocessor-controlled foot prostheses that are commercially available and considered class I devices that are exempt from 510(k) marketing clearance. Information on the Össur website indicates use of the Proprio Foot™ for low- to moderate-impact for transtibial amputees who are classified as level K3 (i.e., community ambulatory, with the ability or potential for ambulation with variable cadence).

POWERED PROSTHESES

In development are lower-limb prostheses that also replace muscle activity in order to bend and straighten the prosthetic joint. For example, the PowerFoot BiOM® (developed at the Massachusetts Institute of Technology and licensed to iWalk) is a myoelectric prosthesis for transtibial amputees that uses muscle activity from the remaining limb for the control of ankle movement. This prosthesis is designed to propel the foot forward as it pushes off the ground during the gait cycle, which in addition to improving efficiency, has the potential to reduce hip and back problems arising from an unnatural gait with use of a passive prosthesis. This technology is limited by the size and the weight required for a motor and batteries in the prosthesis. The Power Knee™ (Össur), which is designed to replace muscle activity of the quadriceps, uses artificial proprioception with sensors similar to the Proprio Foot in order to anticipate and respond with the appropriate movement required for the next step.

REGULATORY STATUS

Microprocessor-controlled prostheses are categorized as class I, exempt devices. Manufacturers must register prostheses with the restorative devices branch of FDA and keep a record of any complaints but do not have to undergo a full FDA review. FDA product codes include ISW and KFX.

EVIDENCE SUMMARY

Evaluating the effects of the increased sophistication of powered knee, powered ankle-foot, and microprocessor-controlled ankle-foot prostheses requires comparison with body-powered prostheses, passive prostheses, or no prosthesis. The most informative data are prospective...
comparative studies with objective measures that directly address function, safety, and health-related quality of life.

The evidence review below does not address microprocessor-controlled knees which have been shown to improve function measures and decrease the cognitive burden associated with monitoring the prosthesis.

MICROPROCESSOR-CONTROLLED ANKLE-FOOT PROSTHESSES

Systematic Reviews

A 2004 Cochrane review of ankle-foot prostheses (assessed as up-to-date through June 2006) concluded that there is insufficient evidence from high quality comparative studies to determine the overall superiority of any individual type of prosthetic ankle-foot mechanism.[1] The review included 26 cross-over studies with 3-16 participants in each study (N=245). Only one study was considered to be of high methodological quality while the remainders were considered of moderate quality. The vast majority of clinical studies on human walking have used standardized gait assessment protocols (e.g., treadmills) with limited “ecological validity”. The authors recommended that for future research, functional outcomes should be assessed for various aspects of mobility such as making transfers, maintaining balance, level walking, stair climbing, negotiating ramps and obstacles, and changes in walking speed.

Randomized Controlled Trials

A 2012 randomized, within-subject crossover study compared self-reported and objective performance outcomes for four types of prosthetic feet, including the SACH (solid ankle cushion heel), SAFE (stationary attachment flexible endoskeletal), Talux mechanical foot, and the Proprio Foot microprocessor-controlled ankle prosthesis.[2] Ten patients with transtibial amputation were tested with their own prosthesis and then, in random order, each of the other prostheses after training and a two week acclimation period. No differences between prostheses were detected for the following measures:

- Prosthesis Evaluation Questionnaire (PEQ) (self-reported subjective rating of ease of use, social and emotional issues, and function over different surfaces)
- Locomotor Capabilities Index (self-reported subjective rating of capability to perform certain activities such as walking in various environments on various surfaces, sitting, standing, bending)
- Six-minute walk test (objective distance measurement)
- Steps per day
- Hours of daily activity

In 2014, the same investigators reported the effects of these prosthetic feet on ramp ambulation in 10 unilateral transtibial amputees.[3] Higher symmetry was reported with the Talux mechanical foot and the Proprio Foot during ramp descent, while no significant difference was found between the prostheses during ramp ascent.

Due to the limited sample sizes in these studies, conclusions cannot be reached about the comparisons between the various types of foot prostheses.

Nonrandomized Comparative Studies
Two comparative trials of the microprocessor-controlled ankle were published since the 2004 Cochrane Review.[4,5] Both studies were from the same investigators and included the Proprio Foot in 16 transtibial amputees during stair ascent and descent[4] or while walking up and down a ramp[5]. These studies were limited to the effect of flexion angles (flexion versus neutral angle). Healthy controls were also used for comparison. The outcomes of these studies were mixed. For example, the adapted mode (ankle flexion) resulted in more normal gait analysis results during ramp ascent but not during descent; however, some patients reported feeling safer with the adaptive mode ankle than with the Proprio Foot. Other small studies have reported on ankle flexion using individuals as their own comparison group.[6] A within-subject study of six patients reported no benefit of an active Proprio Foot compared with the same prosthesis turned off with level walking or with slope ascent or descent.[7] An additional study reported a lower energy cost of floor walking with the Proprio Foot compared with a dynamic carbon fiber foot in 10 transtibial amputees.[8]

Section Summary

These studies do not permit conclusions about the clinical benefits and risks of the microprocessor-controlled foot compared with mechanical prostheses due to methodological limitations. These limitations included but were not limited to the small sample size which limits the ability to rule out chance as an explanation of the study findings.

POWERED KNEE AND/OR ANKLE-FOOT PROSTHESES

Ferris compared the BiOM powered ankle-foot prosthesis with an energy-storing and – returning (ESR) foot in 11 transtibial amputees.[9] These results were also compared with 11 matched controls with intact limbs. Compared with the ESR foot, the powered ankle-foot increased walking speed, but there were no significant differences in physical performance measure or conditions on the PEQ. Compared with the intact limb, the powered ankle-foot had increased step length and greater ankle peak power, but had reduced range of motion. There appeared to be an increase in compensatory strategies at proximal joints with the powered prosthesis; the authors noted that normalization of gait kinematics and kinetics may not be possible with a uniarticular device. Seven patients preferred the PowerFoot BiOM and 4 preferred the ESR prosthesis.

Another small study of seven amputees and seven intact controls reported gross metabolic cost and preferred walking speed to be more similar to non-amputee controls with the powered foot than with the ESR prosthesis.[10]

Mancinelli compared the PowerFoot BiOM with a passive-elastic foot in five transtibial amputees.[11] At the time of this study the powered prosthesis was a prototype and subjects’ exposure to the prosthesis was limited to the laboratory. Laboratory assessment of gait biomechanics showed an average increase of 54% in the peak ankle power generation during late stance. Metabolic cost measured by oxygen consumption while walking on an indoor track was reduced by an average of 8.4% (p=0.06). This study did not report the impact of these measurements on patient function.

Section Summary

The current evidence is insufficient to permit conclusions about the benefits of powered lower extremity prostheses compared with other prostheses. These small studies mainly report on...
the feasibility of various prototypes. Larger, higher quality studies are needed to determine the impact of these devices on functional outcomes with greater certainty.

**PRACTICE GUIDELINE SUMMARY**

The VAs’ Prosthetic and Sensory Aids Strategic Healthcare Group was directed by the Under Secretary for Health to establish a Prosthetic Clinical Management Program to coordinate the development of clinical practice recommendations for prosthetic prescriptive practices. The following are guidelines from the Veterans Health Administration Prosthetic Clinical Management program:

A. Contraindications for use of the microprocessor knee should include:
  - Any condition that prevents socket fitting, such as a complicated wound or intractable pain which precludes socket wear.
  - Inability to tolerate the weight of the prosthesis.
  - Medicare Level K 0—no ability or potential to ambulate or transfer.
  - Medicare Level K 1—limited ability to transfer or ambulate on level ground at fixed cadence.
  - Medicare Level K 2—limited community ambulator that does not have the cardiovascular reserve, strength, and balance to improve stability in stance to permit increased independence, less risk of falls, and potential to advance to a less-restrictive walking device.
  - Inability to use swing and stance features of the knee unit.
  - Poor balance or ataxia that limits ambulation.
  - Significant hip flexion contracture (over 20 degrees).
  - Significant deformity of remaining limb that would impair ability to stride.
  - Limited cardiovascular and/or pulmonary reserve or profound weakness.
  - Limited cognitive ability to understand gait sequencing or care requirements.
  - Long distance or competitive running.
  - Falls outside of recommended weight or height guidelines of manufacturer.
  - Specific environmental factors—such as excessive moisture or dust, or inability to charge the prosthesis.
  - Extremely rural conditions where maintenance ability is limited.

B. Indications for use of the microprocessor knee should include:
  - Adequate cardiovascular and pulmonary reserve to ambulate at variable cadence.
  - Adequate strength and balance in stride to activate the knee unit.
  - Should not exceed the weight or height restrictions of the device.
  - Adequate cognitive ability to master technology and gait requirements of device.
  - Hemi-pelvectomy through knee-disarticulation level of amputation, including bilateral; lower extremity amputees are candidates if they meet functional criteria as listed
  - Patient is an active walker and requires a device that reduces energy consumption to permit longer distances with less fatigue.
  - Daily activities or job tasks that do not permit full focus of concentration on knee control and stability—such as uneven terrain, ramps, curbs, stairs, repetitive lifting, and/or carrying.

These criteria do not imply or guarantee approval. Please check with your plan to ensure coverage. Preauthorization requirements are only valid for the month published. They may have changed from previous months and may change in future months.
• Medicare Level K 2—limited community ambulator, but only if improved stability in stance permits increased independence, less risk of falls, and potential to advance to a less restrictive walking device, and patient has cardiovascular reserve, strength, and balance to use the prosthesis. The microprocessor enables fine-tuning and adjustment of the hydraulic mechanism to accommodate the unique motor skills and demands of the functional level K2 ambulator.
• Medicare Level K 3—unlimited community ambulator.
• Medicare Level K 4—active adult, athlete who has the need to function as a K 3 level in daily activities.
• Potential to lessen back pain by providing more secure stance control, using less muscle control to keep knee stable.
• Potential to unload and decrease stress on remaining limb.
• Potential to return to an active lifestyle.

C. Physical and Functional Fitting Criteria for New Amputees:
• New amputees may be considered if they meet certain criteria as outlined above.
• Premorbid and current functional assessment important determinant.
• Requires stable wound and ability to fit socket.
• Immediate postoperative fit is possible.
• Must have potential to return to active lifestyle.

SUMMARY

Research for microprocessors of the knee have reported improved function for some amputees and a decrease in the cognitive burden associated with monitoring the prosthesis. Those considered most likely to benefit from these prostheses have both the potential and need for frequent movement at a variable pace, uneven ground, or on stairs. Therefore, microprocessors of the knee may be considered medically necessary when policy criteria are met.

There is not enough research to show if or how well microprocessors of the knee improve health outcomes when criteria are not met. Therefore, microprocessors of the knee are not medically necessary, when policy criteria are not met.

There is not enough research to conclude improved health outcomes for microprocessor-controlled ankle-foot prosthesis compared with conventional prostheses. Therefore, microprocessor-controlled ankle-foot prostheses are considered investigational.

There is not enough research to evaluate the health benefits and risks of powered lower limb prostheses. Therefore, powered knee and/or powered ankle-foot prostheses are considered investigational.

REFERENCES


### CODES

<table>
<thead>
<tr>
<th>Codes</th>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>HCPCS</td>
<td>L5856</td>
<td>Addition to lower extremity prosthesis, endoskeletal knee-shin system, microprocessor control feature, swing and stance phase, includes electronic sensor(s), any type</td>
</tr>
<tr>
<td></td>
<td>L5857</td>
<td>;swing phase only, includes electronic sensor(s), any type</td>
</tr>
<tr>
<td></td>
<td>L5858</td>
<td>;stance phase only, includes electronic sensor(s), any type</td>
</tr>
<tr>
<td></td>
<td>L5859</td>
<td>Addition to lower extremity prosthesis, endoskeletal knee-shin system, powered</td>
</tr>
<tr>
<td></td>
<td>L5969</td>
<td>Addition, endoskeletal ankle-foot or ankle system, power assist, includes any type motor(s)</td>
</tr>
</tbody>
</table>

October 1, 2019

These criteria do not imply or guarantee approval. Please check with your plan to ensure coverage. Preauthorization requirements are only valid for the month published. They may have changed from previous months and may change in future months.
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>L5973</td>
<td>Endoskeletal ankle foot system, microprocessor controlled feature, dorsiflexion and/or plantar flexion control, include power source</td>
</tr>
<tr>
<td>L5999</td>
<td>Lower extremity prosthesis, not otherwise specified</td>
</tr>
</tbody>
</table>

*Date of Origin: May 2010*
IMPORTANT REMINDER

Medical Policies are developed to provide guidance for members and providers regarding coverage in accordance with contract terms. Benefit determinations are based in all cases on the applicable contract language. To the extent there may be any conflict between the Medical Policy and contract language, the contract language takes precedence.

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these services.

DESCRIPTION

Myoelectric prostheses and orthotics are powered by electric motors with an external power source. The joint movement of upper limb prostheses or orthoses (e.g., hand, wrist, and/or elbow) is driven by microchip-processed electrical activity in the muscles of the remaining limb or limb stump.

MEDICAL POLICY CRITERIA

I. Myoelectric upper limb prostheses may be medically necessary when all of the following criteria are met (A - F):

   A. The patient has an amputation or missing limb at the wrist or above (forearm, elbow, etc.); and

   B. Standard body-powered prosthetic devices cannot be used or are insufficient to meet the functional needs of the individual in performing activities of daily living; and

   C. The remaining musculature of the arm(s) contains the minimum microvolt threshold to allow operation of a myoelectric prosthetic device, as demonstrated by functional testing using a physical or computer model prosthesis; and
D. The patient has demonstrated sufficient neurological and cognitive function to operate the prosthesis effectively; and

E. The patient is free of comorbidities that could interfere with function of the prosthesis (neuromuscular disease, etc.); and

F. Functional evaluation by a qualified professional (e.g., prosthetist) indicates that with training, use of a myoelectric prosthesis and associated components is necessary to meet the functional needs of the individual (e.g., automatic grasp features, microprocessor control features, or other components to aid gripping, releasing, holding, and coordinating movement of the prosthesis) when performing activities of daily living. This evaluation should consider the patient’s needs for control, durability (maintenance), function (speed, work capability), and usability. Both of the following criteria must be met (1 and 2):

1. The device is necessary for the patient to perform instrumental activities of daily living including job functioning; and

2. The device is not primarily for the purpose of allowing the patient to perform leisure or recreational activities.

II. Myoelectric upper limb prosthetic components are considered not medically necessary under all other conditions including but not limited to replacement of an existing, functioning prostheses (e.g., as an "upgrade" for a prosthesis that still works and fits).

III. Upper-limb prosthetic components with both sensor and myoelectric control are considered investigational.

IV. Myoelectric controlled upper-limb orthoses are considered investigational.

NOTE: A summary of the supporting rationale for the policy criteria is at the end of the policy.

LIST OF INFORMATION NEEDED FOR REVIEW

It is critical that the list of information below is submitted for review to determine if the policy criteria are met. If any of these items are not submitted, it could impact our review and decision outcome.

- History and Physical/Chart Notes
- Documentation of amputation or missing limb at the wrist or above
- Documentation that standard body-powered devices can’t be used or are not efficient including the ADLs that cannot be accomplished currently
- Documentation that the remaining musculature in the limb contains the minimum microvolt threshold to allow operation of the device including a functional test using a physical or computer model prosthesis
- Documentation the patient is cognitively and neurologically able to operate the prosthesis
- Documentation the patient doesn’t have any comorbidities that might interfere with the use of the prosthesis
- An evaluation by a qualified professional such as a prosthetist that show the patient will be able to use the prosthetic for ADLs including the patient’s ability to control, maintain,
function, and use the prosthetic including why it is necessary for the patient to perform ADLs or job functions and evidence it is not being requested only for leisure or recreational activities

- Documentation that the prosthetic is not being requested to replace a functioning prosthetic

**CROSS REFERENCES**

1. [Powered Knee Prosthesis, or Powered Ankle-Foot Prosthesis, and Microprocessor-Controlled Ankle-Foot Prosthesis](#), DME, Policy No. 81

**BACKGROUND**

Upper limb prostheses are used following amputation at any level from the hand to the shoulder. The need for a prosthesis can occur for a number of reasons, including trauma, surgery, or congenital anomalies. The primary goals of the upper limb prosthesis are to restore natural appearance and function. Achieving these goals also requires sufficient comfort and ease of use for continued acceptance by the wearer. The difficulty of achieving these diverse goals with an upper limb prosthesis increases as the level of amputation (digits, hand, wrist, elbow, and shoulder), and thus the complexity of joint movement, increases.

Upper limb prostheses are classified based on the means of generating movement at the joints as follows:

**PASSIVE PROSTHESIS:**

- The lightest weight upper extremity prosthesis
- Patients generally describe this as the most comfortable of the three types
- Must be repositioned manually, typically by moving it with the opposite arm
- Cannot restore function.

**BODY-POWERED PROSTHESIS**

- Uses a body harness and cable system to provide functional manipulation of the elbow and hand. Voluntary movement of the shoulder and/or limb stump extends the cable and transmits the force to the terminal device.
- Prosthetic hand attachments, which may be claw-like devices that allow good grip strength and visual control of objects or latex-gloved devices that provide a more natural appearance at the expense of control, can be opened and closed by the cable system.
- Patient complaints with body-powered prostheses include harness discomfort, particularly the wear temperature, wire failure, and the unattractive appearance.

**MYOELECTRIC PROSTHESIS**

Uses muscle activity from the remaining limb for the control of joint movement.

- Electromyographic (EMG) signals from the limb stump are detected by surface electrodes, amplified, and then processed by a controller to drive battery-powered motors that move the hand, wrist, or elbow.
- Implantable EMG sensors with wireless signal transmission (e.g., Implantable Myoelectric Sensors [IMES®]) are being studied as alternatives to surface electrodes to improve prosthetic hand function. These implantable sensors may eliminate the...
limitations inherent in surface electrodes such as issues related to poor skin contact (e.g., skin sweating) and the ability to detect signals only from superficial muscles.

- Although upper arm movement may be slow and limited to one joint at a time, myoelectric control of movement may be considered the most physiologically natural.
- Myoelectric hand attachments are similar in form to those offered with the body-powered prosthesis, but are battery powered.
- Patient dissatisfaction with myoelectric prostheses includes the increased cost, maintenance (particularly for the glove), and weight.
- Examples of available technologies:
  - The SensorHand™ by Advanced Arm Dynamics, which is described as having an AutoGrasp feature, an opening/closing speed of up to 300 mm/second, and advanced EMG signal processing.
  - The Utah Arm 3 by Motion Control has a microprocessor interface that allows individualized adjustments to achieve maximum performance.
  - The i-LIMB™ hand (Touch Bionics), sometimes referred to as the bionic hand, is the first commercially available myoelectric hand prosthesis with individually powered digits.
  - ProDigits™, also from Touch Bionics, are prosthetic digits for one or more fingers in patients with amputation at a transmetacarpal level or higher.
  - Otto Bock has a number of myoelectric hand and elbow prostheses including the AutoGrasp feature, the Michelangelo® Hand, and the Electrohand 2000 designed for children.
  - LTI Boston Digital Arm™ System by Liberating Technologies Inc. is marketed as having greater torque than any other powered prosthetic elbows
  - These devices may be covered by LIVINGSKIN™, a high-definition silicone prosthesis created to resemble a patient’s natural skin.

SENSOR AND MYOELECTRIC PROSTHESIS

The LUKE Arm (previously known as the DEKA Arm System) can perform complex tasks with multiple simultaneous powered movements (e.g., movement of the elbow, wrist, and hand at the same time). In addition to the EMG electrodes, the LUKE Arm contains a combination of mechanisms including switches, movement sensors, and force sensors. The Luke Arm is the same shape and weight as an adult arm.

HYBRID SYSTEM, A COMBINATION OF BODY-POWERED AND MYOELECTRIC COMPONENTS

- May be used for high-level amputations (at or above the elbow).
- Allows control of two joints at once (i.e., one body-powered and one myoelectric)
- Generally lighter weight and less expensive than a prosthesis composed entirely of myoelectric components.
- An example of a hybrid system is the ErgoArm by Otto Bock which has a myoelectric hand and a cable-controlled elbow joint

Technology in this area is rapidly changing, driven by advances in biomedical engineering and by the U.S. Department of Defense Advanced Research Projects Agency (DARPA), which is funding a public and private collaborative effort on prosthetic research and development. Areas of development include the use of skin-like silicone elastomer gloves, “artificial muscles,” and sensory feedback. Smaller motors, microcontrollers, implantable myoelectric sensors, and re-
innervation of remaining muscle fibers are being developed to allow fine movement control. Lighter batteries and newer materials are being incorporated into myoelectric prostheses to improve comfort.

**MYOELECTRIC ORTHOSES**

The MyoPro (Myomo) is a myoelectric powered upper-extremity orthotic. This orthotic device weighs about 1.8 kilograms (4 pounds), has manual wrist articulation, and myoelectric initiated bi-directional elbow movement. The MyoPro detects weak muscle activity from the affected muscle groups. A therapist or prosthetist/orthoptist can adjust the gain (amount of assistance), signal boost, thresholds, and range of motion. Potential users include patients with traumatic brain injury, spinal cord injury, brachial plexus injury, amyotrophic lateral sclerosis, and multiple sclerosis. Use of robotic devices for therapy has been reported. The MyoPro is the first myoelectric orthotic available for home use.

**Regulatory Status**

Prostheses are class I devices that are exempt from U.S. Food and Drug Administration (FDA) marketing clearance, but manufacturers must register prostheses with the restorative devices branch of the FDA and keep a record of any complaints.

Examples of available myoelectric devices are listed above.

The MyoPro® (Myomo) is registered with the FDA as a class 1 limb orthosis.

---

**EVIDENCE SUMMARY**

In evaluating the effects of the increased sophistication of myoelectric upper limb prostheses compared with body-powered prostheses, passive prostheses, or no prosthesis, the most informative data are from prospective comparative studies with objective and subjective measures that directly address function and health-related quality of life.

In light of the magnitude of functional loss in upper extremity amputation, evaluation of the evidence is based on two assumptions:

1. Use of any prosthesis confers clinical benefit, and
2. Self-selected use is an acceptable measure of the perceived benefit (combination of utility, comfort, and appearance) of a prosthesis for that individual.

It should be considered that the upper limb amputee’s needs may depend on their situation. For example, increased functional capability may be needed with heavy work or domestic duties, while a more natural appearing prosthesis with reduced functional capability may be acceptable for an office, school, or another social environment.

**MYOELECTRIC UPPER LIMB PROSTHESIS**

**Systematic Reviews**

A 2015 systematic review (SR) by Carey evaluated differences between myoelectric and body-powered prostheses. The SR included 31 studies. The evidence was conflicting for functional performance between the two prostheses. The authors concluded that there is insufficient
evidence to show that one system provides a significant advantage over the other and that prosthetic selection should be based on patient preference and functional needs.

A 2007 SR by Biddis of 40 articles published over the previous 25 years assessed upper limb prosthesis acceptance and abandonment.[2] For pediatric patients the mean rejection rate was 38% for passive prostheses (one study), 45% for body-powered prostheses (three studies), and 32% for myoelectric prostheses (12 studies). For adults there was considerable variation between studies, with mean rejection rates of 39% (six studies), 26% (eight studies), and 23% (10 studies) for passive, body-powered and myoelectric prostheses, respectively. The authors found no evidence that the acceptability of passive prostheses had declined over the period from 1983 to 2004, “despite the advent of myoelectric devices with functional as well as cosmetic appeal.” Body-powered prostheses were also found to have remained a popular choice, with the type of hand-attachment being the major factor in acceptance. Body-powered hooks were considered acceptable by many users, but body-powered hands were frequently rejected (80%–87% rejection rates) due to slowness in movement, awkward use, maintenance issues, excessive weight, insufficient grip strength, and the energy needed to operate. Rejection rates of myoelectric prostheses tended to increase with longer follow-up. There was no evidence of a change in rejection rates over the 25 years of study, but the results are limited by sampling bias from isolated populations and the generally poor quality of the studies included.

Randomized Controlled Trials

In comparative studies of prostheses, subjects served as their own control. Since these studies included use by all subjects of both a myoelectric and a body-powered prosthesis, randomization was directed at the order in which each amputee used the prostheses. Two trials were found in which a total of 196 children used both a myoelectric and a body-powered hand prosthesis, in randomized order, for a period of three months each.[3,4] No clinically relevant objective or subjective difference was found between the two types of prostheses.

Nonrandomized Studies

A number of small (n<50) non-randomized case series[5-7] and online or mailed surveys[8-11] were found, but few studies directly addressed whether myoelectric prostheses improved function and health-related quality of life. Most of the studies identified described amputees' self-selected use or rejection rates. The results were usually presented as hours worn at work or school, hours worn at home, and hours worn in social situations. Amputees’ self-reported reasons for use and abandonment were also frequently reported. The limited evidence available suggests that, in comparison with body-powered prostheses, myoelectric components may improve range of motion to some extent, have similar capability for light work, but may have reduced performance under heavy working conditions. The literature also indicated that the percentage of amputees who accepted use of a myoelectric prosthesis was about the same as those who prefer to use a body-powered prosthesis, and that self-selected use depended at least in part on the individual’s activities of daily living. Appearance was most frequently cited as an advantage of myoelectric prostheses. Nonuse of any prosthesis was associated with lack of functional need, discomfort (excessive weight and heat), and impediment to sensory feedback.

Section Summary: Myoelectric Upper-Limb Prosthesis
The identified literature focuses primarily on patient acceptance and rejection; data are limited or lacking in the areas of function and functional status. The limited evidence suggests that the percentage of amputees who accept a myoelectric prosthesis is approximately the same as those who prefer to use a body-powered prosthesis, and that self-selected use depends partly on the individual’s activities of daily living. When compared with body-powered prostheses, myoelectric components possess similar capability to perform light work, and myoelectric components may improve range of motion. The literature has also indicated that appearance is most frequently cited as an advantage of myoelectric prostheses, and for patients who desire a restorative appearance, the myoelectric prosthesis can provide greater function than a passive prosthesis with equivalent function to a body-powered prosthesis for light work.

SENSOR AND MYOELECTRIC UPPER LIMB COMPONENTS

Investigators from three Veterans Administration medical centers and the Center for the Intrepid at Brooke Army Medical Center published a series of reports on home use of the LUKE prototype (DEKA Gen 2 and DEKA Gen 3) in 2017 and 2018.[12-16] Participants were included in the in-laboratory training if they met criteria and had sufficient control options (e.g., myoelectric and/or active control over one or both feet) to operate the device. In-lab training included a virtual reality training component. At the completion of the in-lab training, the investigators determined, using a priori criteria, which participants were eligible to continue to the 12-week home trial. The criteria included the independent use of the prosthesis in the laboratory and community setting, fair, functional performance, and sound judgment when operating or troubleshooting minor technical issues. On ClinicalTrials.gov, the total enrollment target is listed as 100 patients with study completion by February 2018 (NCT01551420).

One of the publications (Resnick, 2017) reported on the acceptance of the LUKE prototype before and after a 12-week trial of home use.[14] Of 42 participants enrolled at the time, 32 (76%) participants completed the in-laboratory training, 22 (52%) wanted to receive a LUKE Arm and proceeded to the home trial, 18 (43%) completed the home trial, and 14 (33%) expressed a desire to receive the prototype at the end of the home trial. Over 80% of those who completed the home trial preferred the prototype arm for hand and wrist function, but as many preferred the weight and look of their own prosthesis. One-third of those who completed the home training thought that the arm was not ready for commercialization. Participants who completed the trial were more likely to be prosthesis users at study onset (p=0.03), and less likely to have musculoskeletal problems (p=0.047).[12] Reasons for attrition during the in-laboratory training were reported in a separate publication by Resnik and Klinger (2017).[15] Attrition was related to the prosthesis entirely or in part by 67% of the participants, leading to a recommendation to provide patients with an opportunity to train with the prosthesis before a final decision about the appropriateness of the device.

Functional outcomes of the Gen 2 and Gen 3 arms, as compared with participants’ prostheses, were reported by Resnick et al (2018).[13] At the time of the report, 23 regular prosthesis users had completed the in-lab training, and 15 had gone on to complete the home use portion of the study. Outcomes were both performance-based and self-reported measures. At the end of the lab training, dexterity was similar, but performance was slower with the LUKE prototype than with their conventional prosthetics. At the end of the home study, activity speed was similar to the conventional prostheses, and one of the performance measures (Activities Measure for Upper-Limb Amputees) was improved. Participants also reported that they were able to perform more activities, had less perceived disability, and less difficulty in activities, but there

These criteria do not imply or guarantee approval. Please check with your plan to ensure coverage.
Preauthorization requirements are only valid for the month published. They may have changed from previous months and may change in future months.
were no differences between the two prostheses on many of the outcome measures including dexterity, prosthetic skill, spontaneity, pain, community integration, or quality of life. Post hoc power analysis suggested that evaluation of some outcomes might not have been sufficiently powered to detect a difference.

In a separate publication, Resnick (2017) reported that participants continued to use their prosthesis (average, 2.7 h/d) in addition to the LUKE prototype, concluding that availability of both prostheses would have the greatest utility.[16] This conclusion is similar to those from earlier prosthesis surveys, which found that the selection of a specific prosthesis type (myoelectric, powered, or passive) could differ depending on the specific activity during the day. In the DEKA Gen 2 and Gen 3 study reported here, 29% of participants had a body-powered device, and 71% had a conventional myoelectric prosthesis.

Section Summary: Sensor and Myoelectric Upper-Limb Components

The LUKE Arm was cleared for marketing in 2014 and is now commercially available. The prototypes for the LUKE Arm, the DEKA Gen 2 and Gen 3, were evaluated by the U.S. military and Veteran’s Administration in a 12-week home study, with study results reported in a series of publications. Acceptance of the advanced prosthesis in this trial was mixed, with one-third of enrolled participants desiring to receive the prototype at the end of the trial. Demonstration of improvement in function has also been mixed. After several months of home use, activity speed was shown to be similar to the conventional prosthesis. There was an improvement in the performance of some, but not all, activities. Participants continued to use their prosthesis for part of the day, and some commented that the prosthesis was not ready for commercialization. There were no differences between the LUKE Arm prototype and the participants’ prostheses for many outcome measures. Study of the current generation of the LUKE Arm is needed to determine whether the newer models of this advanced prosthesis lead to consistent improvements in function and quality of life.

MYOELECTRIC ORTHOTIC

Peters (2017) evaluated the immediate effect (no training) of a myoelectric elbow-wrist-hand orthosis on paretic upper-extremity impairment.[17] Participants (n=18) were stable and moderately impaired with a single stroke 12 months or later before study enrollment. They were tested using a battery of measures without, and then with the device; the order of testing was not counterbalanced. The primary measure was the upper-extremity section of the Fugl-Meyer Assessment, a validated scale that determines active movement. Upper-extremity movement on the Fugl-Meyer Assessment was significantly improved while wearing the orthotic (a clinically significant increase of 8.71 points, p<0.001). The most commonly observed gains were in elbow extension, finger extension, grasping a tennis ball, and grasping a pencil. The Box and Block test (moving blocks from one side of a box to another) also improved (p<0.001). Clinically significant improvements were observed for raising a spoon and cup, and there were significant decreases in the time taken to grasp a cup and gross manual dexterity. Performance on these tests changed from unable to able to complete. The functional outcome measures (raising a spoon and cup, turning on a light switch, and picking up a laundry basket with two hands) were developed by the investigators to assess these moderately impaired participants. The authors noted that performance on these tasks was inconsistent, and proposed a future study that would include training with the myoelectric orthosis before testing.

October 1, 2019

These criteria do not imply or guarantee approval. Please check with your plan to ensure coverage. Preauthorization requirements are only valid for the month published. They may have changed from previous months and may change in future months.
Page (2013) compared the efficacy of a myoelectric orthosis combined with repetitive task-specific practice to repetitive task-specific practice alone in improving performance following stroke.[18] Sixteen subjects at a mean of 75 months post-stroke were divided into two groups. Both groups received therapist-supervised repetitive task-specific practice for three days a week for eight weeks. One group used the orthotic during practice. After intervention, there was no significant difference between groups in Fugl-Meyer score increases, six measures of the Stroke Impact Scale, or Canadian Occupational Performance Measure Performance. There was a significant difference in the Stroke Impact Scale Total (p=0.027).

Section Summary: Myoelectric Orthotic

The largest study identified tested participants with and without the orthosis. This study evaluated the function with and without the orthotic in stable poststroke participants who had no prior experience with the device. Outcomes were inconsistent. Studies are needed that show consistent improvements in relevant outcome measures. Results should also be replicated in a larger number of patients.

PRACTICE GUIDELINE SUMMARY

No practice guidelines identified.

SUMMARY

There is enough research to show that myoelectric upper limb prostheses improve health outcomes for people with an amputation or missing limb at the wrist or above when the medical policy criteria are met. Therefore, myoelectric upper limb prostheses may be considered medically necessary when policy criteria are met.

There is enough research to show that myoelectric upper limb prostheses do not improve health outcomes when policy criteria are not met. Therefore, myoelectric upper limb prostheses, under all other conditions including but not limited to replacement of an existing functioning prostheses are considered not medically necessary when policy criteria are not met.

There is not enough research to show that upper-limb prosthetic components with both sensor and myoelectric control improve health outcomes compared with conventional prostheses. Therefore, upper-limb prosthetic components with both sensor and myoelectric control are considered investigational.

There is not enough research to show that myoelectric controlled upper-limb orthoses improve health outcomes for people with upper limb weakness or paresis. Only two comparative studies have been published examining myoelectric orthoses. They had small sample sizes and demonstrated inconsistent performance. Therefore, myoelectric controlled upper-limb orthoses are considered investigational.

REFERENCES


These criteria do not imply or guarantee approval. Please check with your plan to ensure coverage.
Preauthorization requirements are only valid for the month published. They may have changed from previous months and may change in future months.


**CODES**

<table>
<thead>
<tr>
<th>Codes</th>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>None</td>
<td>Durable medical equipment, miscellaneous</td>
</tr>
<tr>
<td>HCPCS</td>
<td>E1399</td>
<td>Transcarpal/metacarpal or partial hand disarticulation prosthesis, external power, self-suspended, inner socket with removable forearm section, electrodes and cables, two batteries, charger, myoelectric control of terminal device, excludes terminal device(s)</td>
</tr>
<tr>
<td></td>
<td>L6026</td>
<td>Upper extremity addition, locking elbow, forearm counterbalance</td>
</tr>
<tr>
<td></td>
<td>L6693</td>
<td>Terminal device, multiple articulating digit, includes motor(s), initial issue or replacement</td>
</tr>
<tr>
<td></td>
<td>L6715</td>
<td>Electric hand, switch or myoelectric controlled, independently articulating digits, any grasp pattern or combination of grasp patterns, includes motor(s)</td>
</tr>
<tr>
<td></td>
<td>L6880</td>
<td>Automatic grasp feature, addition to upper limb electric prosthetic terminal device</td>
</tr>
<tr>
<td></td>
<td>L6881</td>
<td>Microprocessor control feature, addition to upper limb prosthetic terminal device</td>
</tr>
<tr>
<td></td>
<td>L6882</td>
<td>Wrist disarticulation, external power, self-suspended inner socket, removable forearm shell, Otto Bock or equal electrodes, cables, two batteries and one charger, myoelectric control of terminal device</td>
</tr>
<tr>
<td></td>
<td>L6925</td>
<td>Below elbow, external power, self-suspended inner socket, removable forearm shell, Otto Bock or equal electrodes, cables, two batteries and one charger, myoelectric control of terminal device</td>
</tr>
<tr>
<td></td>
<td>L6935</td>
<td>Elbow disarticulation, external power, molded inner socket, removable humeral shell, outside locking hinges, forearm, Otto Bock or equal electrodes, cables, two batteries and one charger, myoelectric control of terminal device</td>
</tr>
<tr>
<td></td>
<td>L6945</td>
<td>Above elbow, external power, molded inner socket, removable humeral shell, internal locking elbow, forearm, Otto Bock or equal electrodes, cables, two batteries and one charger, myoelectric control of terminal device</td>
</tr>
<tr>
<td></td>
<td>L6955</td>
<td>Shoulder disarticulation, external power, molded inner socket, removable shoulder shell, shoulder bulkhead, humeral section, mechanical elbow, forearm, Otto Bock or equal electrodes, cables, two batteries and one charger, myoelectric control of terminal device</td>
</tr>
<tr>
<td></td>
<td>L6975</td>
<td>Interscapular-thoracic, external power, molded inner socket, removable shoulder shell, shoulder bulkhead, humeral section, mechanical elbow, forearm, Otto Bock or equal electrodes, cables, two batteries and one charger, myoelectric control of terminal device</td>
</tr>
<tr>
<td></td>
<td>L7007</td>
<td>Electric hand, switch or myoelectric controlled, adult</td>
</tr>
<tr>
<td></td>
<td>L7008</td>
<td>Electric hand, switch or myoelectric controlled, pediatric</td>
</tr>
<tr>
<td></td>
<td>L7009</td>
<td>Electric hook, switch or myoelectric controlled, adult</td>
</tr>
<tr>
<td></td>
<td>L7045</td>
<td>Electric hook, switch or myoelectric controlled, pediatric</td>
</tr>
</tbody>
</table>

These criteria do not imply or guarantee approval. Please check with your plan to ensure coverage. Preauthorization requirements are only valid for the month published. They may have changed from previous months and may change in future months.
<table>
<thead>
<tr>
<th>Codes</th>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>L7180</td>
<td>Electronic elbow, microprocessor sequential control of elbow and terminal device</td>
</tr>
<tr>
<td></td>
<td>L7181</td>
<td>Electronic elbow, microprocessor simultaneous control of elbow and terminal device</td>
</tr>
<tr>
<td></td>
<td>L7190</td>
<td>Electronic elbow, adolescent, Variety Village or equal, myoelectronically controlled</td>
</tr>
<tr>
<td></td>
<td>L7191</td>
<td>Electronic elbow, child, Variety Village or equal, myoelectronically controlled</td>
</tr>
<tr>
<td></td>
<td>L7259</td>
<td>Electronic wrist rotator, any type</td>
</tr>
<tr>
<td></td>
<td>L8701</td>
<td>Powered upper extremity range of motion assist device, elbow, wrist, hand with single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated</td>
</tr>
<tr>
<td></td>
<td>L8702</td>
<td>Powered upper extremity range of motion assist device, elbow, wrist, hand, finger, single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated</td>
</tr>
</tbody>
</table>

*Date of Origin: June 2010*
NOTE: This policy is not effective until November 1, 2019.

Noninvasive Ventilators in the Home Setting

Effective: November 1, 2019

Next Review: July 2020
Last Review: July 2019

IMPORTANT REMINDER

Medical Policies are developed to provide guidance for members and providers regarding coverage in accordance with contract terms. Benefit determinations are based in all cases on the applicable contract language. To the extent there may be any conflict between the Medical Policy and contract language, the contract language takes precedence.

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these services.

DESCRIPTION

Noninvasive ventilation (NIV) assistance or noninvasive positive pressure ventilation (NPPV) uses a nasal mask, face mask, or mouthpiece, connected to a ventilator to provide ventilation support during sleep or intermittently throughout the day.

MEDICAL POLICY CRITERIA

Notes: This policy only addresses home ventilators with a noninvasive interface (HCPCS code E0466). It does not address the use of other types of home ventilators, including those with an invasive interface (HCPCS E0465) or a multi-function home ventilator (HCPCS E0467).

I. Use of a noninvasive ventilator in the home setting may be considered medically necessary when both of the following criteria are met (A. and B.):
   A. The device is being requested to treat any of the following indications:
      1. Neuromuscular disease, or
      2. Thoracic restrictive disease, or
3. Chronic respiratory failure consequent to chronic obstructive pulmonary disease.

B. There is sufficient documentation in the medical record to support the condition is life-threatening where interruption of respiratory support would quickly lead to serious harm or death.

II. Use of a noninvasive ventilator in the home setting is considered **not medically necessary** when Criterion I. is not met, including but not limited to the following situations:

A. The patient’s condition is such that treatment may be adequately provided by a bilevel positive airway pressure device; or

B. Severity of the patient’s condition is not severe and life-threatening.

**NOTE:** A summary of the supporting rationale for the policy criteria is at the end of the policy.

**POLICY GUIDELINES**

**VENTILATOR WITH NOINVASIVE INTERFACES**

The Centers for Medicare & Medicaid Services (CMS) National Coverage Determinations Manual (Internet-Only Manual, Publ. 100-03) in Chapter 1, Part 4, Section 280.1 stipulates that ventilators (E0465, E0466) are covered for the following conditions:

“[N]euromuscular diseases, thoracic restrictive diseases, and chronic respiratory failure consequent to chronic obstructive pulmonary disease.”

Each of these disease categories are comprised of conditions that can vary from severe and life-threatening to less serious forms. These ventilator-related disease groups overlap conditions described in this Respiratory Assist Devices LCD used to determine coverage for bi-level PAP devices. Each of these disease categories are conditions where the specific presentation of the disease can vary from patient to patient. For conditions such as these, the specific treatment plan for any individual patient will vary as well. Choice of an appropriate treatment plan, including the determination to use a ventilator vs. a bi-level PAP device, is made based upon the specifics of each individual beneficiary's medical condition. In the event of a claim review, there must be sufficient detailed information in the medical record to justify the treatment selected.

Ventilators fall under the Frequent and Substantial Servicing (FSS) payment category, and payment policy requirements preclude FSS payment for devices used to deliver continuous and/or intermittent positive airway pressure, regardless of the illness treated by the device. (Social Security Act 1834(a)(3)(A)) This means that products currently classified as HCPCS code E0465 or E0466 when used to provide CPAP or bi-level PAP (with or without backup rate) therapy, regardless of the underlying medical condition, shall not be paid in the FSS payment category. A ventilator is not eligible for reimbursement for any of the conditions described in this RAD LCD even though the ventilator equipment may have the capability of operating in a bi-level PAP (E0470, E0471) mode. Claims for ventilators used to provide CPAP or bi-level CPAP therapy for conditions described in this RAD policy will be denied as not reasonable and necessary.

October 1, 2019

These criteria do not imply or guarantee approval. Please check with your plan to ensure coverage. Preauthorization requirements are only valid for the month published. They may have changed from previous months and may change in future months.
General principles of correct coding require that products assigned to a specific HCPCS code only be billed using the assigned code. Thus, using the HCPCS codes for CPAP (E0601) or bilevel PAP (E0470, E0471) devices for a ventilator (E0465, E0466) used to provide CPAP or bilevel PAP therapy is incorrect coding. Claims for ventilators billed using the CPAP or bilevel PAP device HCPCS codes will be denied as incorrect coding.

**LIST OF INFORMATION NEEDED FOR REVIEW**

**REQUIRED DOCUMENTATION:**

The information below **must** be submitted for review to determine whether policy criteria are met. If any of these items are not submitted, it could impact our review and decision outcome.

- All chart notes and medical records pertinent to the request (e.g., supporting documentation of neuromuscular disease, thoracic restrictive disease, and/or chronic respiratory failure consequent to COPD).
- Documentation must demonstrate that the condition is life-threatening where interruption of respiratory support would quickly lead to serious harm or death.

**CROSS REFERENCES**

1. Phrenic Nerve Stimulation for Central Sleep Apnea, Surgery, Policy No. 212

**BACKGROUND**

This policy is based on the Centers for Medicare & Medicaid Services (CMS) National Coverage Determinations Manual (Internet-Only Manual, Publ. 100-03) in Chapter 1, Part 4, Section 280.1; and Local Coverage Determination (LCD): Respiratory Assist Devices (L33800).[1,2]

**NONINVASIVE VENTILATORS**

Ventilators, also known as respirators, are medical devices used to mechanically assist with a patients’ breathing. Mechanical ventilation is often categorized by the interface used, such as a tracheostomy tube for invasive ventilation, or a mask for non-invasive ventilation. Non-invasive ventilation (NIV) assistance or non-invasive positive pressure ventilation (NPPV) uses a nasal mask, face mask, or mouthpiece, connected to a ventilator to provide ventilation support during sleep or intermittently throughout the day. In the hospital setting, a trial of NPPV may be attempted prior to invasive treatment. Ventilation support rests the lung muscles and improves breathing performance during the day. At night, ventilation may be used to treat sleep-associated hypoventilation. If use is at night only, this is referred to as nocturnal NPPV. If use is intermittent, this may be referred to as “Mouthpiece” or “Sip and Puff” ventilation. Supplemental oxygen may also be added to this type of system.

In recent decades, NPPV has been used for treatment in the home setting. BPAP are portable pressure-limited ventilators, and NPPV are portable volume-limited ventilators. In some populations, efficacy is similar with both types of devices according to comparative studies, thus the portable pressure-limited ventilators are usually preferred over portable volume-limited ventilators, because of lower cost, better portability, and often greater comfort. However, NPPV offers more control over breath settings to better refine treatment in more severe, life-threatening conditions.[3]
REGULATORY STATUS

The U.S. Food and Drug Administration (FDA) has approved numerous portable home ventilators through the 510(k) process. A non-exhaustive list of examples includes the following:

- Trilogy™ (Philips Respironics)
- Newport® (Newport Medical Instruments)
- IVent (GE Healthcare)
- Puritan™ (Covidien)
- LTV® (Carefusion)

FDA Product Code: CBK.

SUMMARY

There is enough research to show that use of a noninvasive ventilator in the home setting improves health outcomes for patients with neuromuscular disease, thoracic restrictive disease, or chronic respiratory failure consequent to chronic obstructive pulmonary disease. Clinical guidelines based on research recommend noninvasive ventilators for use in the home setting for these populations. Therefore, the use of a noninvasive ventilator in the home setting may be considered medically necessary when policy criteria are met. In all other situations, there is not enough research to show that the use of a noninvasive ventilator in the home setting improves health outcomes. Therefore, the use of a noninvasive ventilator in the home setting is investigational when policy criteria are not met.

REFERENCES


CODES

**NOTE:** Home ventilator codes requiring prior authorization are listed on the “Commercial Pre-authorization List” web page. Home ventilators not listed on the pre-authorization website do not require prior approval. There may be codes related to home ventilator systems that are not included in this medical policy.

<table>
<thead>
<tr>
<th>Codes</th>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>HCPCS</td>
<td>E0466</td>
<td>Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)</td>
</tr>
</tbody>
</table>

_Date of Origin: December 2018_
Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Conditions

Effective: September 1, 2019

Next Review: June 2020
Last Review: August 2019

IMPORTANT REMINDER

Medical Policies are developed to provide guidance for members and providers regarding coverage in accordance with contract terms. Benefit determinations are based in all cases on the applicable contract language. To the extent there may be any conflict between the Medical Policy and contract language, the contract language takes precedence.

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these services.

DESCRIPTION

Oscillatory devices are used as alternatives to the standard daily percussion and postural drainage (P/PD) method of airway clearance for patients with cystic fibrosis, diffuse bronchiectasis and other respiratory conditions (such as chronic obstructive pulmonary disease).

MEDICAL POLICY CRITERIA

Note: This policy addresses outpatient use of oscillatory devices. Inpatient device use (e.g., in the immediate post-surgical period), is not addressed by this policy.

I. Use of oscillatory positive expiratory pressure (OPEP) devices may be considered medically necessary.

II. Use of high-frequency chest wall oscillation devices (HFCWO) and intrapulmonary percussive ventilation (IPV) devices may be considered medically necessary when either of the following criteria are met:
   A. For patients with cystic fibrosis when all of following criteria (1-2) are met:
1. Demonstrated need for airway clearance, and

2. Documentation of the reason standard chest physiotherapy has failed, is not tolerated, or is unavailable or cannot be performed (e.g., caregiver inability). Failure is defined as continued frequent severe exacerbations of respiratory distress involving inability to clear mucus despite standard treatment (e.g., chest physiotherapy and, if appropriate, use of a positive expiratory pressure device).

B. For patients with chronic diffuse bronchiectasis when all of the following criteria (1-3) are met:

1. Demonstrated need for airway clearance; and

2. Documentation of the reason standard chest physiotherapy has failed, is not tolerated, or is unavailable or cannot be performed (e.g., caregiver inability). Failure is defined as continued frequent severe exacerbations of respiratory distress involving inability to clear mucus despite standard treatment (e.g., chest physiotherapy and, if appropriate, use of a positive expiratory pressure device).

3. Chronic diffuse bronchiectasis must be documented by high resolution or spiral chest computed tomography scan and any one or more of the following must be present:
   a. Daily productive cough for at least six continuous months; or
   b. Exacerbations requiring antibiotic therapy three or more times per year.

III. Use of high-frequency chest wall oscillation (HFCWO) devices and intrapulmonary percussive ventilation (IPV) devices is considered not medically necessary as an alternative to chest physical therapy in patients with cystic fibrosis or chronic bronchiectasis in any other clinical situations.

IV. Other applications of high-frequency chest wall oscillation devices and intrapulmonary percussive ventilation (IPV) devices are considered investigational, including but not limited to the following:

A. Use as an adjunct to chest physical therapy

B. Use in other lung diseases, such as chronic obstructive pulmonary disease or respiratory conditions associated with neuromuscular disorders

NOTE: A summary of the supporting rationale for the policy criteria is at the end of the policy.

LIST OF INFORMATION NEEDED FOR REVIEW

It is critical that the list of information below is submitted for review to determine if the policy criteria are met. If any of these items are not submitted, it could impact our review and decision outcome.

- History and Physical/Chart Notes
- Documentation of specific device being requested
- Documentation of disease process including disease name (e.g. hypersecretory lung disease, cystic fibrosis, chronic diffuse bronchiectasis)
• For high-frequency chest wall oscillation devices (HFCWO) and intrapulmonary percussive ventilation (IPV) include the following:
  o Documentation of need for airway clearance
  o Documentation of why standard chest physiotherapy has failed including reasons, if not tolerated, or is unavailable/cannot be performed including reasons.
  o If patient has chronic diffuse bronchiectasis include documentation by high resolution or spiral chest computed tomography scan along with documentation that there is a daily productive cough that has been present for six continuous months or exacerbations requiring antibiotic therapy three or more times per year.
  o Documentation if the request is going to be an adjunct to chest clinical therapy

CROSS REFERENCES
None

BACKGROUND
Oscillatory devices are designed to move mucus and clear airways; the oscillatory component can be intra- or extrathoracic. Some devices require active participation of patients. They include oscillating positive expiratory pressure (PEP, or OPEP) devices, such as Flutter and Acapella, in which the patient exhales multiple times through a device. The Flutter device is a small pipe-shaped, easily portable handheld device, with a mouthpiece at one end. It contains a high-density stainless steel ball that rests in a plastic circular cone. During exhalation, the steel ball moves up and down, creating oscillations in expiratory pressure and airflow. When the oscillation frequency approximates the resonance frequency of the pulmonary system, vibration of the airways occurs, resulting in loosening of mucus. The Acapella device is similar in concept but uses a counterweighted plug and magnet to create air flow oscillation.

Other airway clearance techniques also require active patient participation. For example, autogenic drainage and active cycle of breathing technique both involve a combination of breathing exercises performed by the patient. PEP therapy requires patients to exhale through a resistor to produce PEPs during a prolonged period of exhalation. It is hypothesized that the positive pressure supports the small airway such that the expiratory airflow can better mobilize secretions.

In contrast, high-frequency chest wall oscillation (HFCWO) devices (e.g., the Vest Airway Clearance System, formerly the ABI Vest, or the ThAIRapy Bronchial Drainage System) are oscillatory devices designed to provide airway clearance without the active participation of the patient. The Vest Airway Clearance System provides high-frequency chest compression using an inflatable vest and an air-pulse generator. Large-bore tubing connects the vest to the air-pulse generator. The air-pulse generator creates pressure pulses that cause the vest to inflate and deflate against the thorax, creating HFCWO and mobilization of pulmonary secretions.

The Percussionaire oscillatory device delivers intrapulmonary percussive ventilation. This device combines internal thoracic percussion through rapid minibursts of inhaled air and continuous therapeutic aerosol delivered through a nebulizer.

All of these techniques can be used as alternatives to daily percussion and postural drainage, also known as chest physical therapy, in patients with cystic fibrosis. Daily percussion and
postural drainage need to be administered by a physical therapist or another trained adult in the home, typically a parent if the patient is a child. The necessity for regular therapy can be particularly burdensome for adolescents or adults who lead independent lifestyles. Oscillatory devices can also potentially be used by patients with other respiratory disorders to promote bronchial secretion drainage and clearance, such as diffuse bronchiectasis and chronic obstructive pulmonary disease. In addition, they could benefit patients with neuromuscular disease who have impaired cough clearance.

REGULATORY STATUS

The following are examples of high frequency chest wall oscillation (HFCWO), and intrapulmonary percussive ventilation (IPV) devices that have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510K approval process. FDA product codes: BYI, BYT.

Table 1. Examples of high frequency chest wall oscillation (HFCWO) and intrapulmonary percussive ventilation (IPV) devices. This list may not encompass all HFCWO and IPV devices.

<table>
<thead>
<tr>
<th>Device</th>
<th>Device Type</th>
<th>Manufacturer</th>
<th>FDA number</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABI® Vest System</td>
<td>high frequency chest wall oscillation (HFCWO)</td>
<td>American Biosystems, Inc.</td>
<td>K993629</td>
</tr>
<tr>
<td>AffloVest</td>
<td>HFCWO</td>
<td>International Biophysics Corporation</td>
<td>K122480</td>
</tr>
<tr>
<td>Bird IPV®</td>
<td>Intrapulmonary percussive ventilation (IPV)</td>
<td>Percussionaire Corp.</td>
<td>K895485</td>
</tr>
<tr>
<td>Monarch® Airway Clearance System</td>
<td>HFCWO</td>
<td>Hill-Rom</td>
<td>K163378</td>
</tr>
<tr>
<td>SmartVest® SQL® System</td>
<td>HFCWO</td>
<td>Electromed, Inc.</td>
<td>K132794</td>
</tr>
<tr>
<td>SmartVest SV2100 System</td>
<td>HFCWO</td>
<td>Electromed, Inc.</td>
<td>K053248</td>
</tr>
<tr>
<td>ThAIRaphy®</td>
<td>HFCWO</td>
<td>American Biosystems, Inc.</td>
<td>K965192</td>
</tr>
<tr>
<td>Vest® Airway Clearance System</td>
<td>HFCWO</td>
<td>Hill-Rom</td>
<td>K142482,  K024309</td>
</tr>
</tbody>
</table>

The following are examples of OPEP devices that have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510K approval process. FDA product codes: BYI, BYT.

Table 2. Non-exhaustive list of oscillatory positive expiratory pressure (OPEP) devices which are not reviewed by this policy.

<table>
<thead>
<tr>
<th>Device</th>
<th>Manufacturer</th>
<th>FDA number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acapella®</td>
<td>Smiths Medical, Inc.</td>
<td>K002768</td>
</tr>
<tr>
<td>Aerobika Oscillating Positive Expiratory Pressure (OPEP)</td>
<td>Trudell Medical</td>
<td>K123400</td>
</tr>
<tr>
<td>Aerobika OPEP with Manometer</td>
<td>Trudell Medical</td>
<td>K150173</td>
</tr>
<tr>
<td>Aerosure Medic</td>
<td>Actegy Ltd.</td>
<td>K140772</td>
</tr>
<tr>
<td>Device</td>
<td>Manufacturer</td>
<td>FDA number</td>
</tr>
<tr>
<td>-------------------------------------------------</td>
<td>--------------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>Flutter® Mucus Clearance Device</td>
<td>Axcan Scandipharm, Inc.</td>
<td>K946083, K940986, K972859</td>
</tr>
<tr>
<td>Lung Flute®</td>
<td>Medical Acoustics LLC</td>
<td>K091557</td>
</tr>
<tr>
<td>MetaNeb® 4 System</td>
<td>Hill-Rom</td>
<td>K151689</td>
</tr>
<tr>
<td>RC-Cornet™</td>
<td>PARI Respiratory Equipment</td>
<td>K983308</td>
</tr>
<tr>
<td>Roadrunner</td>
<td>DHD Healthcare</td>
<td>K991561</td>
</tr>
<tr>
<td>PARI PEP</td>
<td>PARI Respiratory Equipment, Inc.</td>
<td>K972042</td>
</tr>
<tr>
<td>PARI PEP S Positive Expiratory Pressure Device</td>
<td>PARI Respiratory Equipment, Inc.</td>
<td>K090829</td>
</tr>
<tr>
<td>TheraPEP®</td>
<td>Smiths Medical, Inc.</td>
<td>K9944900, K962749, K983467</td>
</tr>
<tr>
<td>Vibralung Acoustical Percussor</td>
<td>Westmed Inc.</td>
<td>K133057</td>
</tr>
<tr>
<td>VibraPEP™</td>
<td>Curaplex</td>
<td>K153441</td>
</tr>
</tbody>
</table>

**EVIDENCE SUMMARY**

Evaluating the safety and effectiveness of any oscillatory device requires randomized comparisons with standard airway clearance techniques (e.g., percussion and postural drainage). These comparisons are necessary to determine whether the benefits of oscillatory devices outweigh any risks and whether they offer advantages over conventional methods with respect to increasing quality of life and decreasing long-term morbidity and mortality, or secondary outcomes such as improved mucus clearance, lung function or rate of respiratory exacerbations.

**CYSTIC FIBROSIS**

**Systematic Review**

A 2014 updated Cochrane review evaluated oscillating devices for the treatment of cystic fibrosis.[1,2] Investigators searched the literature for randomized controlled trials (RCTs) comparing oscillatory devices to another recognized airway clearance technique. A total of 35 RCTs with 1,050 patients met inclusion criteria. Fifteen studies used a parallel design and 20 were crossover studies. The majority (16 studies) were conducted in the United States. Sample sizes of individual studies ranged from 5 to 166, and half the studies included children. Outcomes included pulmonary function, sputum weight and volume, hospitalization rate, and quality of life measures. Due to the variety of devices used, outcome measures and lengths of follow-up, a quantitative meta-analysis of multiple studies could not be performed. The authors concluded that there was a lack of evidence supporting any one airway clearance technique or device over another, and that adequately powered RCTs with long-term follow-up were needed.

**Randomized Controlled Trials**

Overall, RCTs are underpowered have not found clear advantages of one oscillatory device over another.[3,4] Details on studies with a minimum of one year follow-up are as follows:
McIlwaine (2013) published an RCT comparing two types of oscillatory devices. This study differed from previous trials, because it had a larger sample size (n=107) and the primary outcome measure was a clinically meaningful outcome, i.e., the number of pulmonary exacerbations requiring an antibiotic. In addition, the study was conducted over a relatively long time period (one year), was a multicenter trial, and was not industry-funded, although industry did donate devices. The study included individuals over six years of age with clinically stable cystic fibrosis; age ranged from 6 to 47 years. Patients were randomized to perform either positive expiratory pressure (PEP) using a face mask (n=51) or high frequency chest wall oscillation (HFCWO) using the inCourage system (n=56) for one year. After randomization, there was a two-month washout period (without knowledge of treatment group assignment). Eight patients in each arm dropped out after randomization and before treatment, and another three patients dropped out during the intervention phase. A total of 88 of 107 (82%) randomized patients completed the study. By the end of one year, there were 49 exacerbations requiring antibiotics in the PEP group and 96 in the HFCWO group; the difference between groups was statistically significant, favoring PEP (p=0.007). The time to first pulmonary exacerbation was 220 days in the PEP group and 115 days in the HFCWO group (p=0.02). There was not a statistically significant difference in pulmonary measures, including FEV1. Limitations of this study were that patients were not blinded and there was nearly a 20% drop-out rate. The trial was stopped early without enrolling the expected number of patients and, thus, may have been underpowered to detect clinically significant differences between groups.

Sontag and colleagues conducted a multicenter randomized trial with 166 adults and children with cystic fibrosis. Patients were assigned to receive treatment with P/PD (n=58), the Flutter® device (n=51), or the Vest (n=57). Investigators planned to evaluate participants on a quarterly basis for 3 years. However, dropout rates were high and consequently the trial ended early; 35 (60%), 16 (31%) and 5 (9%) patients withdrew from the postural drainage, Flutter®, and Vest groups, respectively. Fifteen patients withdrew in the first 60 days (11 of these on the day of randomization) and the remainder after 60 days. The most common reasons for withdrawal after 60 days were moved or lost to follow-up (n=13), and lack of time (n=7). At study termination, patients had a final assessment; the length of participation ranged from 1.3 to 2.8 years. An intention-to-treat (ITT) analysis found no significant differences between treatment groups in the modeled rate of decline for FEV1 predicted or forced vital capacity (FVC%) predicted. The small sample size and high dropout rate greatly limit the conclusions that might be drawn from this study.

**Section Summary**

A number of RCTs and a systematic review (SR) have been published. RCTs had mixed findings and limitations such as small sample sizes and large dropout rates. The SR identified 35 RCTs comparing oscillatory devices with another recognized airway clearance techniques; some were published only as abstracts. Study findings could not be pooled due heterogeneity in design and outcome measures. The SR concluded that additional RCTs are needed that are adequately powered and have long-term follow-up.

**BRONCHIECTASIS**

**Systematic Reviews**

Lee (2015) published a Cochrane review on airway clearance techniques for treating bronchiectasis. Seven RCTs comparing airway clearance techniques with sham or an
alternative treatment were identified.\cite{8-14} One hundred and five total patients were included; sample sizes ranged from 8 to 37. All studies, except one (N=37), were crossover trials. Five trials used a PEP device, one used HFCWO, and one used postural drainage. The investigators did not pool study findings due to heterogeneity among studies. Primary outcomes of interest to the Cochrane reviewers were exacerbations, hospitalizations for bronchiectasis, and quality of life (QOL). Only one trial, a crossover study with 20 patients, reported exacerbations. This trial, published by Murray (2009), did not find a statistically significant difference at 12 weeks in the number of exacerbations (there were five exacerbations with the oscillating PEP device vs seven without the oscillating PEP device; \( p=0.48 \)).\cite{10} Cough-related QOL was significantly better after 12 weeks of any airway clearance technique compared with no airway clearance. Three studies reported QOL outcomes. The Murray trial found significantly better health-related quality of life (HRQOL) with a PEP device compared with control, though a study by Svenningen did not. The third study, by Nicolini, used HFCWO and found significantly better HRQOL with the oscillatory device than with control.\cite{11} The Cochrane reviewers noted that the studies were not blinded and that patient-reported QOL measures may have been subject to bias.

**Randomized Controlled Trials**

RCTs evaluating HFCWO or IPV devices for bronchiectasis were not identified.

**CHRONIC OBSTRUCTIVE PULMONARY DISEASE**

**Systematic Reviews**

Systematic reviews evaluating HFCWO or IPV devices for chronic obstructive pulmonary disease were not identified.

**Randomized Controlled Trials**

Goktalay (2013) published a study that included 50 patients with stage 3-4 COPD who were hospitalized for COPD exacerbations.\cite{15} Patients were randomized to receive five days of treatment with medical therapy plus HCFWO using the Vest Airway Clearance System (n=25) or medical therapy-only (n=25). At day five, outcomes, including FEV1, scores on the MMRC dyspnea scale and the six-minute walk test, did not differ significantly between groups. This was a short-term study and included hospitalized patients who may not be similar to COPD patients treated on an outpatient basis.

Chakrovorty (2011) published a randomized cross-over study evaluating use of high-frequency chest wall oscillation in patients with moderate to severe COPD and mucus hypersecretion.\cite{16} Patients received HFCWO or conventional treatment, in random order, for four weeks, with a two-week wash-out period between treatments. Thirty patients enrolled in the study and 22 (73%) completed the trial; eight patients withdrew due to COPD exacerbations. The primary outcome was quality of life which was measured with the St. George’s Respiratory Questionnaire (SGRQ). Only one out of four dimensions of the SGRQ (the symptom dimension) improved after HFCWO compared to before treatment, with a decrease in the mean score from 72 to 64 (\( p=0.02 \)). None of the four dimensions of the SGRQ improved after conventional treatment. There were no significant differences in secondary outcomes such as FEV1 or FVC after either treatment compared to before treatment. The study was limited by small sample size, the relatively high drop-out rate, and lack of intention to treat analysis.

**RESPIRATORY CONDITIONS RELATED TO NEUROMUSCULAR DISORDERS**
A 2014 Cochrane review on nonpharmacologic management of respiratory morbidity in children with severe global developmental delay addressed airway clearance techniques.[17] The review included RCTs and nonrandomized comparative studies. Three studies were identified on HFCWO (one RCT, two pre-post) and one on PEP (pre-post). Sample sizes ranged from 15 and 28 patients.

The RCT, published by Yuan (2010), compared HCFWO to standard chest physical therapy in 28 patients with cerebral palsy or neuromuscular disease attending a pediatric pulmonary clinic.[18] Both groups were instructed to perform the assigned treatment for 12 minutes three times a day for the study period (mean, five months). Twenty-three (82%) of 28 patients completed the study; all five dropouts were in the HCFWO group. The authors noted that the trial was exploratory and was not powered to detect statistically significant findings on of the primary outcomes (e.g., incidence and duration of acute respiratory infection requiring inpatient or patient antibiotics, adverse effects of treatment). There were no statistically significant differences between groups on primary outcomes. For example, four patients required inpatient intravenous antibiotics in the standard physical therapy group and none in the HCFWO group (p=0.09). In addition, seven patients required oral antibiotics in the standard physical therapy group and three in the HFCWO group (p=NS). No therapy-related adverse events were reported in either group. No subsequent RCTs published after their Cochrane review was identified on oscillatory devices in children with neuromuscular diseases.

In addition to the pediatric studies included in the Cochrane review, one RCT, published by Lange (2006) was identified on HFCWO in adults with amyotrophic lateral sclerosis (ALS).[19] The trial included 46 patients with probable or definite ALS with respiratory conditions as evidenced by score on the ALS Functional Rating Scale (ALSFRS) respiratory subscale between 6 and 11 (the subscale range, 0 [complete ventilator support] to 12 [normal]). Patients were randomized to 12 weeks of HCFWO or usual care. The primary end points were measures of pulmonary function after 12 weeks. Data were available for 35 (76%) of 46 patients at 12 weeks. There were no statistically significant between-group differences in pulmonary measures (FVC predicted, capnography, oxygen saturation, or peak expiratory flow). There was also no significant difference in the ALSFRS respiratory subscale score (worsening) at 12 weeks. Of symptoms assessed as secondary outcomes, there was significantly less breathlessness and night cough in the HCFWO group than in the usual care group, and groups did not differ significantly on other symptoms, including noise of breathing, suction frequency, suction amount, day cough, and nocturnal symptoms.

**PRACTICE GUIDELINE SUMMARY**

**AMERICAN COLLEGE OF CHEST PHYSICIANS**

The 2006 guidelines from the American College of Chest Physicians (ACCP) recommended (level of evidence; low) that in patients with cystic fibrosis, devices designed to oscillate gas in the airway, either directly or by compressing the chest wall, can be considered as an alternative to chest physiotherapy.[20]

**CYSTIC FIBROSIS FOUNDATION**

In April 2009, the Cystic Fibrosis Foundation (CFF) published guidelines on airway clearance therapies based on a SR of evidence.[21] They recommend airway clearance therapies for all patients with cystic fibrosis but state that no therapy has been demonstrated to be superior to others (level of evidence, fair; net benefit, moderate; grade of recommendation, B). They also
issued a consensus recommendation that the prescribing of airway clearance therapies should be individualized based on factors such as age and patient preference.

SUMMARY

OSCILLATORY POSITIVE EXPIRATORY PRESSURE (OPEP)

There is enough research to show that oscillatory positive expiratory pressure (OPEP) devices improve health outcomes. Practice guidelines based on research recommend the use of OPEP devices. Therefore, oscillatory positive expiratory pressure devices may be considered medically necessary.

HIGH-FREQUENCY CHEST WALL OSCILLATION DEVICES (HFCWO) AND INTRAPULMONARY PERCUSSIVE VENTILATION (IPV) DEVICES

There is enough research to show that high-frequency chest wall oscillation devices (HFCWO) and intrapulmonary percussive ventilation (IPV) devices improve health outcomes for people with cystic fibrosis or chronic diffuse bronchiectasis. Therefore, HFCWO and IPV may be considered medically necessary when the policy criteria are met.

There is not enough research to show that high-frequency chest wall oscillation devices (HFCWO) and intrapulmonary percussive ventilation (IPV) devices are a medically necessary alternative to chest physical therapy in patients with cystic fibrosis or chronic bronchiectasis, in any other clinical situations. Therefore, HFCWO and IPV are considered not medically necessary as an alternative to chest physical therapy in patients with cystic fibrosis or chronic bronchiectasis when the policy criteria are not met.

There is not enough research to show that high-frequency chest wall oscillation devices (HFCWO) and intrapulmonary percussive ventilation (IPV) devices improve health outcomes as an adjunct to chest physical therapy or for people with chronic obstructive pulmonary disease (COPD) and respiratory conditions associated with neuromuscular disorders. Therefore, the use of HFCWO and IPV devices as an adjunct to chest physical therapy or for patients with chronic obstructive pulmonary disease (COPD) and respiratory conditions associated with neuromuscular disorders is considered investigational.

REFERENCES


These criteria do not imply or guarantee approval. Please check with your plan to ensure coverage. Preauthorization requirements are only valid for the month published. They may have changed from previous months and may change in future months.


## CODES

### NOTES:

- Devices have codes specific to their technology, e.g., IPV is reported by E0481.
- Oscillatory positive expiratory pressure (OPEP) are reported by E0484 and S8185.

<table>
<thead>
<tr>
<th>Codes</th>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>HCPCS</td>
<td>A7025</td>
<td>High frequency chest wall oscillation system vest, replacement for use with patient-owned equipment, each</td>
</tr>
<tr>
<td></td>
<td>A7026</td>
<td>High frequency chest wall oscillation system hose, replacement for use with patient-owned equipment, each</td>
</tr>
<tr>
<td></td>
<td>E0481</td>
<td>Intrapulmonary percussive ventilation system and related accessories</td>
</tr>
<tr>
<td></td>
<td>E0483</td>
<td>High frequency chest wall oscillation system, includes all accessories and supplies, each</td>
</tr>
</tbody>
</table>

*Date of Origin: May 2011*
NOTE: This policy is not effective until November 1, 2019.

**Medical Policy Manual**  
**Durable Medical Equipment**, Policy No. 37

**Power Wheelchairs: Group 3**

**Effective:** November 1, 2019

**Next Review:** July 2020  
**Last Review:** July 2019

**IMPORTANT REMINDER**

Medical Policies are developed to provide guidance for members and providers regarding coverage in accordance with contract terms. Benefit determinations are based in all cases on the applicable contract language. To the extent there may be any conflict between the Medical Policy and contract language, the contract language takes precedence.

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these services.

**DESCRIPTION**

Power wheelchairs are battery powered mobility devices with integrated or modular seating system, electronic steering and four or more wheel non-highway construction.

**MEDICAL POLICY CRITERIA**

**Note:** This policy only addresses Group 3 power wheelchairs (HCPCS codes K0848-K0864).

I. **All** of the following general criteria (A. – L.) must be met for a Group 3 power wheelchair to be considered for coverage:

   A. The patient has had a specialty evaluation that was performed by a licensed/certified medical professional, such as a PT or OT, or practitioner who has specific training and experience in rehabilitation wheelchair evaluations and that documents the medical necessity for the wheelchair and its special features; and

   B. The patient has a mobility limitation that significantly impairs their ability to participate in one or more mobility-related activities of daily living (MRADLs) such
as toileting, feeding, dressing, grooming, and bathing in customary locations in the home. A mobility limitation is one that:

1. Prevents the member from accomplishing a MRADL entirely, or
2. Places the patient at reasonably determined heightened risk of morbidity or mortality secondary to the attempts to perform a MRADL, or
3. Prevents the member from completing MRADLs within a reasonable time frame.

C. Use of a power wheelchair will significantly improve the patient’s ability to participate in MRADLs and the patient will use it in the home. For patients with severe cognitive and/or physical impairments, participation in MRADLs may require the assistance of a caregiver; and

D. The patient does not have sufficient upper extremity function to self-propel an optimally-configured manual wheelchair in the home to perform MRADLs during a typical day. Notes: Limitations of strength, endurance, range of motion, or coordination, presence of pain, or deformity or absence of one or both upper extremities are relevant to the assessment of upper extremity function.

E. The underlying condition is not reversible and the length of need is more than 3 months; and

F. The patient’s mobility limitation cannot be sufficiently and safely resolved by the use of an appropriately fitted cane or walker; and

G. The patient is not a candidate for a power operated vehicle; and

H. The patient has the mental (e.g., cognition, judgment) and physical (e.g., vision) capabilities to safely operate the power wheelchair that is provided, in the home setting; or if the patient is unable to safely operate the power wheelchair, the patient has a caregiver who is unable to adequately propel an optimally configured manual wheelchair, but is available, willing, and able to safely operate the power wheelchair that is provided; and

I. The patient’s weight is less than or equal to the weight capacity of the PWC that is provided and greater than or equal to 95% of the weight capacity of the next lower weight class, i.e., a Heavy Duty PWC is covered for a patient weighing 285 – 450 pounds; a Very Heavy Duty PWC is covered for a patient weighing 428 – 600 pounds; an Extra Heavy Duty PWC is covered for a patient weighing 570 pounds or more.

J. The patient’s home provides adequate access between rooms, maneuvering space, and surfaces for the operation of the power wheelchair that is provided; and

K. The patient has not expressed an unwillingness to use a power wheelchair in the home; and

L. Any coverage criteria pertaining to the specific wheelchair type (see below) are met.

II. Any of the following Group 3 power wheelchairs may be considered medically necessary when all of Criteria I. above are met:

These criteria do not imply or guarantee approval. Please check with your plan to ensure coverage. Preauthorization requirements are only valid for the month published. They may have changed from previous months and may change in future months.
A. A Group 3 PWC with no power options (K0848-K0855) when the patient’s mobility limitation is due to a neurological condition, myopathy, or congenital skeletal deformity.

B. A Group 3 PWC with single power option (K0856-K0860) or multiple power option (K0861-K0864) when both of the following (1. and 2.) are met:

1. The patient’s mobility limitation is due to a neurological condition, myopathy, or congenital skeletal deformity; and

2. Any one of the following are met:
   a. The patient requires a drive control interface other than a hand or chin-operated standard proportional joystick (examples include but are not limited to head control, sip and puff, switch control); or
   b. The patient uses a ventilator which is mounted on the wheelchair; or
   c. The patient has a power tilt or a power recline seating system and the system is being used on the wheelchair and one of the following are met:
      i. The patient is at high risk for development of a pressure ulcer and is unable to perform a functional weight shift; or
      ii. The patient utilizes intermittent catheterization for bladder management and is unable to independently transfer from the wheelchair to bed; or
      iii. The power seating system is needed to manage increased tone or spasticity.

III. Group 3 power wheelchairs are considered **not medically necessary** when the above criteria are not met, including but not limited to the following:

A. The patient is capable of ambulation within the home but requires a wheelchair for movement outside the home; or

B. The primary benefit of the wheelchair is to allow the patient to perform leisure or recreational activities; or

C. The patient has been approved for a power operated vehicle (POV); or

D. The accessory is used for the convenience of the patient or caregiver and is not necessary for performance of mobility related activities of daily living (MRADLs); or

E. The underlying condition is reversible and the length of need is less than 3 months (e.g., following lower extremity surgery which limits ambulation).

**NOTE:** A summary of the supporting rationale for the policy criteria is at the end of the policy.

**POLICY GUIDELINES**

**APPROPRIATE POPULATIONS**

Group 3 power wheelchairs are reserved for the severely impaired patient afflicted with diseases such as: Amyotrophic Lateral Sclerosis (ALS), spinal cord injuries resulting in
quadriplegia, stroke (CVA) with hemiplegia, late stage Parkinson's, late stage Multiple Sclerosis (MS), cerebral palsy or Muscular Dystrophy.[1]

A group 3 power wheelchair would not be appropriate for a beneficiary who has diabetes with peripheral neuropathy. Peripheral neuropathy affects the nerves. It is not a primary neurological condition but rather a symptom of another disease. The Power Mobility Device LCD specifically states that the patient must have a neurological condition; therefore, the beneficiary with peripheral neuropathy does not meet coverage criteria for a group 3 power wheelchair.

LIST OF INFORMATION NEEDED FOR REVIEW

REQUIRED DOCUMENTATION:

The information below must be submitted for review to determine whether policy criteria are met. If any of these items are not submitted, it could impact our review and decision outcome.

- Medical records and chart notes pertinent to the PWC request, including history of the present condition(s) and past medical history relevant to mobility needs. Required information includes:
  - Date of face-to-face examination by the treating practitioner, with signed and dated documentation;
  - Elements of the face-to-face should include:
    - Mobility limitation and how it interferes with the performance of ADLs (the physical examination should focus on body systems responsible for ambulatory difficulty or impact on ambulatory ability);
    - Explanation of why a cane, walker, manual wheelchair, or POV (scooter) is unable to meet the mobility needs in the home; and,
    - If the member has the physical and mental abilities to operate a power wheelchair safely in the home.
  - The underlying condition, and whether or not it is reversible.
  - Ambulation-limiting symptoms and the diagnoses responsible for them;
  - Medications or other treatment for these symptoms;
  - Progression of ambulation difficulty over time;
  - Other diagnoses that may relate to ambulatory problems;
  - How far the beneficiary can walk without stopping and the pace of ambulation;
  - What ambulatory assistance (e.g., cane, walker, wheelchair, caregiver) currently used. If the prior mobility device is not a POV, provide details regarding the physical and functional changes that now require the use of a power mobility device;
  - Ability to stand up from a seated position without assistance; and,
  - Description of the home setting and the ability to perform activities of daily living in the home.
  - Length of need
  - Physical examination relevant to mobility needs;
    - Weight and height;
    - Cardiopulmonary examination;

These criteria do not imply or guarantee approval. Please check with your plan to ensure coverage.

Preauthorization requirements are only valid for the month published. They may have changed from previous months and may change in future months.
Musculoskeletal examination (i.e., arm and leg strength and range of motion);
Neurological examination (i.e., gait, balance and coordination); and,
Clearly distinguish the beneficiary’s abilities and needs within the home from any additional needs for use outside the home.

**CROSS REFERENCES**

None

**BACKGROUND**

Wheelchairs can be described in HCPCS coding with one code for the wheelchair base and then additional codes for wheelchair options and accessories. The decision for a particular wheelchair base may be influenced by the chair's intended use, the patient's size or level of disability, or based on specific features that will be incorporated into the chair (for example, a heavy-duty base with additional electronics features may be needed to support a power tilt and/or recline option.)

The following is a list of wheelchair bases and their characteristics:

**POWER WHEELCHAIRS (PWCS)**

Power wheelchairs are battery powered mobility devices with integrated or modular seating system, electronic steering and four or more wheel non-highway construction. PWCs are divided into six performance-based groups as listed in Table 1.[2] This policy only addresses Group 3 PWCS:

**Table 1. Power Wheelchairs: Six Performance-based Groups**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Length</td>
<td>40 inches</td>
<td>48 inches</td>
<td>48 inches</td>
<td>48 inches</td>
<td>48 inches</td>
<td>NA</td>
</tr>
<tr>
<td>Width</td>
<td>&lt;24 inches</td>
<td>&lt;34 inches</td>
<td>&lt;34 inches</td>
<td>&lt;34 inches</td>
<td>&lt;34 inches</td>
<td>NA</td>
</tr>
<tr>
<td>Obstacle Height</td>
<td>20 mm</td>
<td>40 mm</td>
<td>60 mm</td>
<td>75 mm</td>
<td>60 mm</td>
<td>NA</td>
</tr>
<tr>
<td>Minimum Top End Speed-Flat</td>
<td>3 MPH</td>
<td>3 MPH</td>
<td>4.5 MPH</td>
<td>6 MPH</td>
<td>4 MPH</td>
<td>NA</td>
</tr>
<tr>
<td>Range</td>
<td>5 miles</td>
<td>7 miles</td>
<td>12 miles</td>
<td>16 miles</td>
<td>12 miles</td>
<td>NA</td>
</tr>
</tbody>
</table>

Obstacle height or obstacle climb denotes the vertical height of a solid obstruction that can be climbed.
Minimum top end speed denotes the minimum speed on a flat hard surface that is acceptable for a given category of devices.
Range denotes the minimum distance acceptable for a given category of devices on a single charge of the batteries.
The above six PWC groups are subdivided based on patient weight capacity, seat type, portability and/or power seating system capability.

There are four weight capacity groups. Those listed in Table 2. represent patient weight handling capacity and are not intended to reflect performance.

**Table 2. Weight Capacity Groups**

These criteria do not imply or guarantee approval. Please check with your plan to ensure coverage. Preauthorization requirements are only valid for the month published. They may have changed from previous months and may change in future months.
<table>
<thead>
<tr>
<th>Standard Duty</th>
<th>Heavy Duty</th>
<th>Very Heavy Duty</th>
<th>Extra Heavy Duty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up to and including 300 pounds</td>
<td>301-450 pounds</td>
<td>451-600 pounds</td>
<td>601 pounds or more</td>
</tr>
</tbody>
</table>

**Table 3. Seat Types**

<table>
<thead>
<tr>
<th>Sling Seat/Back- Flexible</th>
<th>Solid Seat/ Back- Rigid</th>
<th>Captains Chair</th>
<th>Stadium Style Seat</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cloth, vinyl, leather or equal material designed to serve as the support for buttocks or back. They may or may not have thin padding but are not intended to provide cushioning or positioning for the user.</td>
<td>Metal or plastic material usually covered with cloth, vinyl, leather or equal material, with or without some padding material designed to serve as the support for the buttocks or back. They may or may not have thin padding but are not intended to provide cushioning or positioning for the user. PWCs with an automotive-style back and a solid seat pan are considered as a solid seat/back system, not a Captains Chair.</td>
<td>A one or two-piece automotive-style seat with rigid frame, cushioning material in both seat and back sections, covered in cloth, vinyl, leather or equal as upholstery, and designed to serve as a complete seating, support, and cushioning system for the user. It may have armrests that can be fixed, swingaway, or detachable. It may or may not have a headrest, either integrated or separate.</td>
<td>A one or two piece stadium-style seat with rigid frame and cushioning material in both seat and back sections, covered in cloth, vinyl, leather or equal as upholstery, and designed to serve as a complete seating, support, and cushioning system for the user. It may have armrests that can be fixed, swingaway, or detachable. It does not have a headrest. Chairs with stadium style seats are billed using the Captains Chair HCPCS codes.</td>
</tr>
</tbody>
</table>

Portable denotes a PWC that is built of lightweight construction or can be disassembled into lightweight components that allow easy placement into a vehicle for use in a distant location.

Power options that may be added to a PWC to include power tilt, recline, elevating legrests, seat elevators or standing systems. There are three categories of PWCs based on the capability to accept and operate these power options:

- **No-power-options** PWCs are incapable of accommodating any power options
- **Single power option** PWCs have the capability to accept and operate only one power accessory at a time on the base.
- **Multiple power option** PWCs have the capability to accept and operate more than one power accessory at a time on the base.

Pediatric PWCs are uniquely sized for use with very small individuals and have the capability for extensive growth through frame adjustments (not just seating) and special features to address developmental issues (e.g., seat to floor placement, standing capability).

Each power wheelchair base code is intended to include all of the following Basic Equipment Package items on initial issue:

- Lap belt or safety belt (E0978)
- Battery charger single mode (E2366)
Complete set of tires and casters, any type
Legrests: Fixed, swingaway, or detachable nonelevating leg rests with or without calf pad (E0995)
Footrests: Fixed, swingaway, or detachable nonelevating foot rests/plates or foot platform without angle adjustment for any PWC or angle adjustable footplates with Group 1 or 2 PWCs (K0037, K0040, K0041, K0042, K0043, K0044, K0045, K0052)
Fixed, swingaway, or detachable nonadjustable height armrests (E0994, K0015, K0019) with arm pad (K0019)
Upholstery for seat and back of proper strength and type for patient weight capacity of the power wheelchair (E0981, E0982)
Weight specific components per patient weight capacity
Any seat width and depth or back width except for Group 3 or 4 PWCs with a sling/solid seat/back
Controller and Input Device.

SUMMARY

Group 3 power wheelchairs may improve overall health outcomes for some people with mobility limitations. According to the U.S. Centers for Medicare & Medicaid Services, Group 3 power wheelchairs are considered reasonable and medically necessary for specific populations when certain situations exist. Therefore, Group 3 power wheelchairs may be considered medically necessary when policy criteria are met. In all other situations, Group 3 power wheelchair use does not change management and does not improve health outcomes. Therefore, Group 3 power wheelchairs are not medically necessary when policy criteria are not met.

REFERENCES

CODES

NOTE: This policy only addresses Group 3 PWC (HCPCS codes K0848-K0864).

<table>
<thead>
<tr>
<th>Codes</th>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>HCPCS</td>
<td>K0848</td>
<td>Power wheelchair, group 3 standard, sling/solid seat/back, patient weight capacity up to and including 300 pounds</td>
</tr>
<tr>
<td></td>
<td>K0849</td>
<td>Power wheelchair, group 3 standard, captains chair, patient weight capacity up to and including 300 pounds</td>
</tr>
<tr>
<td></td>
<td>K0850</td>
<td>Power wheelchair, group 3 heavy duty, sling/solid seat/back, patient weight capacity 301 to 450 pounds</td>
</tr>
<tr>
<td></td>
<td>K0851</td>
<td>Power wheelchair, group 3 heavy duty, captains chair, patient weight capacity 301 to 450 pounds</td>
</tr>
<tr>
<td></td>
<td>K0852</td>
<td>Power wheelchair, group 3 very heavy duty, sling/solid seat/back, patient weight capacity 451 to 600 pounds</td>
</tr>
<tr>
<td></td>
<td>K0853</td>
<td>Power wheelchair, group 3 very heavy duty, captains chair, patient weight capacity 451 to 600 pounds</td>
</tr>
<tr>
<td></td>
<td>K0854</td>
<td>Power wheelchair, group 3 extra heavy duty, sling/solid seat/back, patient weight capacity 601 pounds or more</td>
</tr>
<tr>
<td></td>
<td>K0855</td>
<td>Power wheelchair, group 3 extra heavy duty, captains chair, patient weight capacity 601 pounds or more</td>
</tr>
<tr>
<td></td>
<td>K0856</td>
<td>Power wheelchair, group 3 standard, single power option, sling/solid seat/back, patient weight capacity up to and including 300 pounds</td>
</tr>
<tr>
<td></td>
<td>K0857</td>
<td>Power wheelchair, group 3 standard, single power option, captains chair, patient weight capacity up to and including 300 pounds</td>
</tr>
<tr>
<td></td>
<td>K0858</td>
<td>Power wheelchair, group 3 heavy duty, single power option, sling/solid seat/back, patient weight capacity 301 to 450 pounds</td>
</tr>
<tr>
<td></td>
<td>K0859</td>
<td>Power wheelchair, group 3 heavy duty, single power option, captains chair, patient weight capacity 301 to 450 pounds</td>
</tr>
<tr>
<td></td>
<td>K0860</td>
<td>Power wheelchair, group 3 very heavy duty, single power option, sling/solid seat/back, patient weight capacity 451 to 600 pounds</td>
</tr>
<tr>
<td></td>
<td>K0861</td>
<td>Power wheelchair, group 3 standard, multiple power option, sling/solid seat/back, patient weight capacity up to and including 300 pounds</td>
</tr>
<tr>
<td></td>
<td>K0862</td>
<td>Power wheelchair, group 3 heavy duty, multiple power option, sling/solid seat/back, patient weight capacity 301 to 450 pounds</td>
</tr>
<tr>
<td></td>
<td>K0863</td>
<td>Power wheelchair, group 3 very heavy duty, multiple power option, sling/solid seat/back, patient weight capacity 451 to 600 pounds</td>
</tr>
<tr>
<td></td>
<td>K0864</td>
<td>Power wheelchair, group 3 extra heavy duty, multiple power option, sling/solid seat/back, patient weight capacity 601 pounds or more</td>
</tr>
</tbody>
</table>

Date of Origin: July 2019
**Programmable Pneumatic Compression Pumps**

**Effective:** June 1, 2019

**Next Review:** April 2020  
**Last Review:** April 2019

**IMPORTANT REMINDER**

Medical Policies are developed to provide guidance for members and providers regarding coverage in accordance with contract terms. Benefit determinations are based in all cases on the applicable contract language. To the extent there may be any conflict between the Medical Policy and contract language, the contract language takes precedence.

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these services.

**DESCRIPTION**

Compression pumps may be used to reduce swelling, help circulation, and prevent blood clot formation in immobilized patients.

**MEDICAL POLICY CRITERIA**

**Note:** This policy addresses only single- or multi-chamber programmable pumps described by HCPCS code E0652. This policy does **not** address single- or multi-chamber non-programmable pumps, which are considered a standard of care for the treatment of lymphedema, prevention of venous thromboembolism in high risk patients, and chronic venous insufficiency.

I. Single- or multi-chamber programmable pneumatic compression (lymphedema) pumps applied to the limb (HCPCS code E0652) may be considered **medically necessary** for the treatment of lymphedema when any of the following are met:

   A. Lack of adequate clinical response after use of a single- or multi-chamber non-programmable pneumatic compression pump; or

   B. There is documentation that the individual has unique characteristics that prevent satisfactory pneumatic compression with single- or multi-chamber non-
programmable pneumatic compression pumps, including but not limited to significant scarring, fibrosis, or anatomic variations.

II. Single- or multi-chamber programmable pneumatic compression pumps are considered not medically necessary when criterion I is not met.

NOTE: A summary of the supporting rationale for the policy criteria is at the end of the policy.

LIST OF INFORMATION NEEDED FOR REVIEW

It is critical that the list of information below is submitted for review to determine if the policy criteria are met. If any of these items are not submitted, it could impact our review and decision outcome.

- History and Physical/Chart Notes
- Documentation of unique characteristics that prevent satisfactory pneumatic compression with single- or multi-chamber non-programmable lymphedema pumps or documentation of a lack of adequate clinical response of a non-programmable pump.

CROSS REFERENCES

None

BACKGROUND

Multi-chamber programmable pneumatic compression pumps may be used to lessen the accumulation of fluids in the arms, legs or trunk, to treat chronic venous insufficiency, or to prevent blood clot formation in immobile patients. Similar in action to the way a blood pressure cuff inflates and deflates, these devices provide air compression to segmented sleeves that are wrapped around the limbs or trunk. These multi-chambered sleeves can be individually adjusted to allow different pressures (gradient pressure) in each segment.

EVIDENCE SUMMARY

Assessment of efficacy for therapeutic interventions involves a determination of whether the intervention improves health outcomes. The optimal study design for a therapeutic intervention is a randomized controlled trial (RCT) that includes clinically relevant measures of health outcomes. Intermediate outcome measures, also known as surrogate outcome measures, may also be adequate if there is an established link between the intermediate outcome and true health outcomes. Nonrandomized comparative studies and uncontrolled studies can sometimes provide useful information on health outcomes, but are prone to biases such as selection bias (e.g., noncomparability of treatment groups) and observation bias (e.g., the placebo effect).

SYSTEMATIC REVIEWS

Ezzo (2015) published a systematic review (SR) that included six randomized or quasi-randomized trials that were divided into three categories based on similar design.[1] Only one study[2] included compression therapy using pneumatic pumps. This quasi-randomized, controlled trial (RCT) compared compression sleeve plus manual lymphedema drainage (MLD) to compression sleeve plus intermittent pneumatic pump in 24 women with post-mastectomy
arm lymphedema. Both groups reported a statistically significant improvement in sensations of heaviness compared to baseline. Volume reduction was statistically better in the MLD group than in the pneumatic pump group, though no significant difference was found for percent reduction, strength, or range of motion. Adverse effects were not reported. The limitations of the included study were the lack of assessor blinding, the small patient population, and the short-term follow-up period of four weeks. In addition, this study was published in 1998 and may not reflect the outcomes from newer technologies.

RANDOMIZED CONTROLLED TRIALS

No high quality RCTs were identified that compared the effectiveness of multi-chamber programmable pneumatic compression pumps with either single compartment or multi-chamber non-programmable pneumatic compression pumps.

NON-RANDOMIZED COMPARATIVE STUDIES

Data on the effectiveness of pneumatic compression devices is limited. The evidence consists primarily of small non-randomized studies for a variety of single and multi-chamber pumps.[3-5] Evidence from these studies does not permit conclusion about the effectiveness and safety of these pumps due to methodological limitations including but not limited to the following:

- Non-random allocation of treatment which may introduce selection or response bias.
- Lack of blinding may bias treatment effect estimates.
- Lack of appropriate comparison groups which does not permit conclusions on the efficacy of multi-chamber programmable pumps compared to other available pumps.
- Variable pump protocols limit effective analysis across studies because it is difficult to determine whether a treatment effect is related to the pump type or protocol used.
- Small study populations which limit the ability to rule out the role of chance as an explanation of findings.
- Variable patient baseline characteristics such as severity of conditions (e.g., lymphedema) which may bias treatment effect estimates.

ADVERSE EVENTS

Concerns about damage to remaining intact lymphatics caused by too high pump pressures have been reported; however, these concerns are not well quantified in the literature.

PRACTICE GUIDELINE SUMMARY

SOCIETY FOR VASCULAR SURGERY AND AMERICAN VENOUS FORUM

The Society for Vascular Surgery and the American Venous Forum performed a systematic review and published a 2014 guideline on the management of venous ulcers. The guideline included the following statement on pneumatic compression: "We suggest use of intermittent pneumatic compression when other compression options are not available, cannot be used, or have failed to aid in venous leg ulcer healing after prolonged compression therapy.[6] The recommendation is based on Grade - 2; Level of Evidence - C (Very weak recommendations; Other alternatives may be reasonable)."
SUMMARY

It appears that single- or multi-chamber programmable pneumatic compression pumps may improve health outcomes for some people with lymphedema. Clinical guidelines based on research recommend the use of single- or multi-chamber programmable pneumatic compression pumps in certain situations. Therefore, single- or multi-chamber programmable pneumatic compression pumps may be considered medically necessary to treat lymphedema when policy criteria are met.

There is not enough research to show that single- or multi-chamber programmable pneumatic compression pumps improve health outcomes in patients with lymphedema when policy criteria are not met. Therefore, single- or multi-chamber programmable pneumatic compression pumps are considered not medically necessary when policy criteria are not met.

REFERENCES


CODES

<table>
<thead>
<tr>
<th>Codes</th>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>HCPCS</td>
<td>E0652</td>
<td>Pneumatic compressor, segmental home model with calibrated gradient pressure</td>
</tr>
<tr>
<td></td>
<td>E0671</td>
<td>Segmental gradient pressure pneumatic appliance, full leg</td>
</tr>
</tbody>
</table>

These criteria do not imply or guarantee approval. Please check with your plan to ensure coverage. Preauthorization requirements are only valid for the month published. They may have changed from previous months and may change in future months.
<table>
<thead>
<tr>
<th>Codes</th>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>E0672</td>
<td>Segmental gradient pressure pneumatic appliance, full arm</td>
</tr>
<tr>
<td></td>
<td>E0673</td>
<td>Segmental gradient pressure pneumatic appliance, half leg</td>
</tr>
</tbody>
</table>

*Date of Origin: November 2009*
Important upcoming pre-authorization changes

- **Pharmacy: Infusion Drug Site of Care** - effective January 1, 2020
- **Physical Medicine**
  - Physical therapy, speech therapy, occupational therapy (PT/OT/ST) - effective March 1, 2020
    - PEBB: UMP Classic, UMP CDHP and UMP Plus - Limit 60 annual visits
    - SEBB: UMP Achieve 1, UMP Achieve 2, UMP High Deductible - Limit 80 annual visits
    - SEBB: UMP Plus - Limit 60 annual visits
  - Pain management - effective January 1, 2020
  - Joint management - effective January 1, 2020
  - Spine - effective January 1, 2020
- **Radiology** - effective January 1, 2020
- **Sleep Medicine** - effective January 1, 2020

**Pharmacy**

UMP has a separate vendor – Washington State Rx Services – for their prescription drug benefit. Pre-authorization is necessary for certain injectable drugs that are not normally approved for self-administration when obtained through a retail pharmacy, a network mail-order pharmacy, or a network specialty pharmacy. These drugs are indicated on the UMP Preferred Drug List.

Drugs usually payable under the member’s medical benefit and pre-authorized will continue with the same Regence process.

**Infusion Drug Site of Care**

Effective January 1, 2020: Certain provider administered infusion medications covered on the medical benefit are subject to the [Site of Care Program (dru408) medication policy (PDF)](#). This policy does not apply to members covered under UMP Plus plans.
Physical Medicine

We partner with eviCore healthcare to administer our Physical Medicine program.

Providers obtain or verify an authorization with eviCore:

1. Sign in to eviCore's portal
2. Phone (855) 252-1115
3. Fax (855) 774-1319

If HTCC criteria is used for authorization – see below for links to that criteria

Effective March 1, 2020: Physical therapy, speech therapy, occupational therapy (PT/ST/OT)

- Members aged 17 and younger: Select pediatric diagnosis codes are excluded from the program (PDF).
- We require authorization from eviCore for these codes: 92507, 92508, 92521, 92522, 92523, 92524, 92526, 92597, 92607, 92608, 92609, 92610, 92626, 92627, 92630, 92633, 95831, 95832, 95833, 95834, 95851, 95852, 96105, 97012, 97014, 97016, 97018, 97022, 97024, 97026, 97028, 97032, 97033, 97034, 97035, 97036, 97039, 97110, 97112, 97113, 97116, 97127, 97139, 97150, 97161, 97162, 97163, 97164, 97165, 97166, 97167, 97168, 97530, 97533, 97542, 97750, 97755, 97760, 97761, 97763, 97799, G0151, G0152, G0157, G0158, G0159, G0160, G0283, G0515, S8950, S9128, S9129, S9131, S9152

Effective March 1, 2020: HTCC decisions administered by eviCore related to physical therapy, speech therapy, occupational therapy

- Treatment of chronic migraine and chronic tension-type headache
  - UMP is subject to HTCC Decision (PDF): 97140

Effective January 1, 2020: Pain management

- We require authorization from eviCore for these codes: 00640, 27096, 61790, 61791, 62320, 62321, 62322, 62323, 62324, 62325, 62326, 62327, 62350, 62351, 62360, 62361, 62362, 64405, 64510, 64520, 72275, G0259, G0260

These criteria do not imply or guarantee approval. Please check with your plan to ensure coverage. Preauthorization requirements are only valid for the month published. They may have changed from previous months and may change in future months.
Effective January 1, 2020: HTCC decisions administered by eviCore related to pain management

- Discography
  - UMP is subject to [HTCC Decision (PDF)](https://example.com): 62290, 62291, 72285, 72295
- Facet Neurotomy
  - UMP is subject to [HTCC Decision (PDF)](https://example.com): 64633, 64634, 64635, 64636
- Spinal Injections
  - UMP is subject to [HTCC Decision (PDF)](https://example.com): 62320, 62321, 62322, 62323, 64479, 64480, 64483, 64484, 64490, 64491, 64492, 64493, 64494, 64495
  - This coverage policy does not apply to those with systemic inflammatory disease such as ankylosing spondylitis, psoriatic arthritis or enteropathic arthritis

Effective January 1, 2020: Joint management

- We require authorization from eviCore for these codes: 23470, 23472, 23473, 23474, 27125, 27130, 27132, 27134, 27137, 27138, 27442, 27443, 27486, 27487, 27488, 27580, 29805, 29806, 29807, 29819, 29820, 29821, 29822, 29823, 29824, 29825, 29826, 29827, 29828, 29860, 29861, 29862, 29863, 29868, 29870, 29871, 29873, 29875, 29876, 29879, 29880, 29881, 29882, 29883, 29884, 29885, 29886, 29887, 29888, 29889, 29891, 29892, 29893, 29894, 29895, 29897, 29898, 29899, 29904, 29905, 29906, 29907

Effective January 1, 2020: HTCC decisions administered by eviCore related to joint management

- Hip Surgery for Femoroacetabular Impingement Syndrome (FAI)
  - UMP is subject to [HTCC Decision (PDF)](https://example.com): 29914, 29915, 29916
- Knee Arthroscopy for Osteoarthritis of the Knee
  - UMP is subject to [HTCC Decision (PDF)](https://example.com): 29874, 29877
- Total Knee Arthroplasty
  - UMP is subject to [HTCC Decision (PDF)](https://example.com): 27437, 27438, 27440, 27441, 27445, 27446, 27447

Effective January 1, 2020: Spine

- We require authorization from eviCore for these codes: 20931, 20937, 20938, 22100, 22101, 22102, 22103, 22110, 22112, 22114, 22116,
Effective January 1, 2020: HTCC decisions administered by eviCore related to spine

- **Cervical Fusion for Degenerative Disc Disease**
  - UMP is subject to [HTCC Decision (PDF)](22551, 22552, 22554, 22853, 22854, 22859, 22600)

- **Lumbar Fusion for Degenerative Disc Disease**
  - UMP is subject to [HTCC Decision (PDF)](22533, 22558, 22612, 22630, 22633, 22853, 22854, 22859)
  - Lumbar Fusion for degenerative disc disease uncomplicated by comorbidities is not a covered benefit per HTCC Decision
  - Note: This decision does not apply to patients with the following conditions: radiculopathy, spondylolisthesis (>grade 1), severe spinal stenosis, acute trauma or systemic disease affecting spine, e.g., malignancy
  - UMP is subject to [HTCC Decision (PDF)](22533, 22558, 22612, 22630, 22633) for Bone Morphogenic Protein
  - Bone morphogenetic protein-7 (rhBMP-7) is not a covered benefit
  - HTCC for bone morphogenetic protein does not apply to those under age 18

- **Surgery for Lumbar Radiculopathy**
  - UMP is subject to [HTCC Decision (PDF)](62380, 63030, 63035, 63042, 63044, 63047, 63048, 63056, 63057, 63090, 63091)
Radiology

AIM Specialty Health

We partner with AIM to administer our Advanced Imaging Authorization radiology program. Providers:

- Login to AIM’s ProviderPortal
- Phone 1 (877) 291-0509

NOTE: If HTCC criteria is used for pre-authorization, see below for links to that criteria. If there are no HTCC criteria, AIM criteria will apply.

Effective January 1, 2020: Contact AIM to obtain an order number for the following codes: 70336, 70480, 70481, 70482, 70490, 70491, 70492, 70496, 70498, 70544, 70545, 70546, 70547, 70548, 70549, 70551, 70552, 70553, 71250, 71260, 71270, 71275, 71550, 71551, 71552, 71555, 72125, 72126, 72127, 72128, 72129, 72130, 72131, 72132, 72133, 72141, 72142, 72146, 72147, 72148, 72149, 72156, 72157, 72158, 72159, 72191, 72192, 72193, 72194, 72195, 72196, 72197, 72198, 73200, 73201, 73202, 73206, 73218, 73219, 73220, 73221, 73222, 73223, 73225, 73700, 73701, 73702, 73706, 73718, 73719, 73720, 73721, 73722, 73723, 73725, 74150, 74160, 74170, 74174, 74175, 74176, 74177, 74178, 74181, 74182, 74183, 74185, 74712, 75557, 75559, 75561, 75563, 75572, 75573, 75635, 77078, 77084, 78472, 78473, 78481, 78483, 78494, 93303, 93304, 93306, 93307, 93308, 93312, 93313, 93314, 93315, 93316, 93317, 93350, 93351, G0297, 0501T, 0502T, 0503T, 0504T

Effective January 1, 2020: HTCC decisions administered by AIM

- Breast MRI
  o UMP is subject to HTCC Decision (PDF): 77046, 77047, 77048, 77049
  o HTCC criteria applies to all member requests regardless of gender
- Cardiac Nuclear Imaging
  o UMP is subject to HTCC Decision (PDF): 78451, 78452, 78453, 78454, 78459, 78466, 78468, 78469, 78491, 78492
- Coronary Computed Tomographic Angiography (CTA)
  o UMP is subject to HTCC Decision (PDF): 75574
- Functional Neuroimaging for Primary Degenerative Dementia or Mild Cognitive Impairment
  o UMP is subject to HTCC Decision (PDF): 70554, 70555, 78608, 78609
Please see AIM criteria for pre-authorization requirements for indications other than primary degenerative dementia or mild cognitive impairment

- **Imaging for Rhinosinusitis**
  - UMP is subject to HTCC Decision (PDF): 70450, 70460, 70470, 70486, 70487, 70488, 70540, 70542, 70543
  - Please see AIM criteria for pre-authorization requirements for indications other than Rhinosinusitis

- **Positron Emission Tomography (PET) Scans for Lymphoma**
  - UMP is subject to HTCC Decision (PDF): 78811, 78812, 78813, 78814, 78815, 78816

---

### Sleep Medicine

We partner with AIM to administer our Sleep Medicine program. Providers:

- Login to AIM’s ProviderPortal
- Phone 1 (877) 291-0509

**Effective January 1, 2020: contact AIM to obtain an order number for the following codes: 95782, 95783, 95805, E0470, E0471**

AIM uses HTCC to pre-authorize sleep medicine diagnosis and equipment. Also refer to the Surgery section for additional information about Sleep Apnea Diagnosis and Treatment.

**Effective January 1, 2020: HTCC decisions administered by AIM:**

- **Sleep Apnea – Diagnosis and Equipment**
  - UMP is subject to HTCC Decisions (PDF): 95800, 95801, 95806, 95807, 95808, 95810, 95811, E0561, E0562, E0601, G0398, G0399, G0400
  - Please see AIM criteria for indications other than Sleep Apnea
Medication Policy Manual

Policy No: dru408

Topic: Site of Care Review

Date of Origin: July 10, 2015

Committee Approval Date: July 24, 2019

Next Review Date: July 2020

Effective Date: October 1, 2019

Description

This policy is to review the requested site of care (SOC) for provider-administered medications. Many medications historically infused in hospital-based infusion centers have been evaluated and determined to be safe for infusion outside of hospital-based settings. Use of non-hospital-based infusion centers and home infusion services is an accepted standard medical practice and sometimes referred to as an “alternate site of care.” These settings offer high-quality services for patients and reduce the overall cost of care, as compared to costly hospital-based infusion centers.

This policy applies to fully-insured commercial plans, exchange plans, and select self-insured groups [a.k.a. administrative-services only (ASO)] based in Washington, Oregon, Idaho, and Utah. This policy does not apply to Medicare plans.

IMPORTANT REMINDER

This Medication Policy has been developed through consideration of medical necessity, generally accepted standards of medical practice, and review of medical literature and government approval status.

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control.

Description

The purpose of medication policy is to provide a guide to coverage. Medication Policy is not intended to dictate to providers how to practice medicine. Providers are expected to exercise their medical judgment in providing the most appropriate care.
Policy/Criteria

I. Under most contracts, medications included in the infusion drug site of care program (see Appendix 1) may be considered medically necessary when individual medication policy criteria are met AND one of the following criteria (A. or B.) below are met:

A. The medication is administered in an approved site of care. (No formal “Site of Care” review is required)

OR

B. The medication is administered in an unapproved site of care (see Appendix 2), such as an unapproved hospital-based infusion center, when at least one of the criteria below (1. or 2.) are met:

NOTE: Site of care review criteria will be waived for payment of the first dose of a medication, to allow for adequate transition time to an approved site of care for subsequent infusions.

1. There is no nearby approved site of care AND home infusion is not an option, as documented by criteria a. AND b. being met:
   a. All approved sites of care are greater than 10 miles further from the member’s home than from the unapproved site of care, such as an unapproved hospital-based infusion center (example: the member’s house is 41 miles from an approved site of care, but 30 miles to the unapproved site of care).
   AND
   b. The member’s home is not eligible for home infusion services for reasons including, but not limited to: the home is not within the service area of the home infusion provider or is deemed unsuitable for care by the home infusion provider, unless the medication is not eligible for home infusion services (see Appendix 1)

OR

2. Clinical documentation of at least one medical reason why an approved site of care is not an option, including, but not limited to:
   i. The member is 13 years of age or younger.
   ii. Significant behavioral issues and/or cognitive impairment including, but not limited to, those associated with developmental delay, down syndrome, dementia, or excessive anxiety such as severe needle phobia.
   iii. Prior severe infusion reactions, despite standard pre-medications.
   iv. Presence of circulating antibodies which may increase risk of infusion reactions.
   v. Treatment within 100 days after hematopoietic stem cell transplantation (HSCT, a.k.a. bone marrow transplant).

October 1, 2019

These criteria do not imply or guarantee approval. Please check with your plan to ensure coverage. Preauthorization requirements are only valid for the month published. They may have changed from previous months and may change in future months.
vi. Concurrent treatment with medications that require a higher level of monitoring (such as CAR T-cell therapy, intravenous cytotoxic chemotherapy, or blood products).

vii. Treatment of antibody-mediated rejection (a.k.a. vascular rejection, acute humoral rejection) following a solid organ transplant.

viii. Treatment of Kawasaki disease.

II. Limitations and Authorization Period – Authorization **shall** be reviewed at least annually to confirm that current medical necessity criteria are met, including that an approved site of care is still not a treatment option.

III. The medications in the infusion drug site of care program are considered not medically necessary if administered in an unapproved site of care, such as an unapproved hospital-based infusion center, when an approved site of care is a treatment option.

Position Statement

- New technologies and pharmaceuticals allow therapeutic services, such as infusion therapy, to be administered safely, effectively, and much less costly outside of hospital-based infusion centers (a.k.a. hospital outpatient settings). Sites of care such as doctor’s offices, infusion centers, home infusion, and approved hospital-based infusion centers are well-established, accepted by physicians, and provide the best value to patients to reduce the overall cost of care.

Site of Care Review:

- Use of non-hospital-based infusion centers and home infusion services is an accepted standard medical practice. These sites offer high-quality services for patients and reduce the overall cost of care, as compared to costly hospital-based infusion centers. [1-8]

- All medications infused outside of a hospital setting have undergone an evaluation for safe infusion and development of infusion standards, including adverse drug reaction management and reporting algorithms.

- At all sites of care, every patient undergoes an assessment during the intake process by the infusion provider, which includes evaluation of individual clinical assessment parameters. These parameters may include, but are not limited to, previous tolerance of products (such as IVIG), assessment of kidney function, risk factors for developing thromboembolic events, and venous access. [9-10]

- For use of home infusion services, an assessment is conducted to determine if the home is a safe, appropriate site of care, with adequate support for infusion in the home.

- Because providers need time to arrange for assessment and coordination of care, the first dose of provider-administered medications may be covered in a hospital-based infusion center, if needed, to allow adequate time for a seamless transition of care. This may include arranging for delivery of medications and/or patient education, such as for self-administration of medications such as subcutaneous immune globulin (SCIG).
- Claims submitted for infusion services performed at an unapproved site of care, such as an unapproved hospital-based infusion center (such as on campus or off campus hospital outpatient settings, denoted by place of service codes 22 or 19; see Appendix 3), are considered not medically necessary when an approved site of care is a treatment option.

- Pediatric patients often differ from adult patients in physiology, development, and cognitive and emotional function. They may also require doses, infusion rates, and equipment that vary and differ compared to adult patients. Special infusion training and expertise is needed. Therefore, this policy allows for patients aged 13 years and younger to obtain infusion services in approved sites of care or unapproved sites of care, such as unapproved hospital-based infusion centers.

### Appendix 1: Medications Included in the Infusion Drug Site of Care Program

<table>
<thead>
<tr>
<th>Medication</th>
<th>Effective Date</th>
<th>Policy Number</th>
<th>Home infusion eligible</th>
<th>HCPCS Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actemra, tocilizumab a</td>
<td>3/1/2015</td>
<td>dru444</td>
<td>Yes</td>
<td>J3262</td>
</tr>
<tr>
<td>Adagen, pegademase bovine</td>
<td>4/1/2016</td>
<td>dru426</td>
<td>Yes</td>
<td>J2504</td>
</tr>
<tr>
<td>Aldurazyme, laronidase</td>
<td>4/1/2016</td>
<td>dru426</td>
<td>Yes</td>
<td>J1931</td>
</tr>
<tr>
<td>Benlysta, belimumab</td>
<td>9/1/2015</td>
<td>dru248</td>
<td>Yes</td>
<td>J0490</td>
</tr>
<tr>
<td>Cerelzyme, imiglucerase</td>
<td>4/1/2017</td>
<td>dru002</td>
<td>Yes</td>
<td>J1786</td>
</tr>
<tr>
<td>Cimzia, certolizumab pegol a</td>
<td>3/1/2018</td>
<td>dru444</td>
<td>Yes</td>
<td>J0717</td>
</tr>
<tr>
<td>Crysvita, buromunab</td>
<td>11/1/2019</td>
<td>dru547</td>
<td>Yes</td>
<td>J0584</td>
</tr>
<tr>
<td>Elaprase, idursulfase</td>
<td>4/1/2017</td>
<td>dru426</td>
<td>Yes</td>
<td>J1743</td>
</tr>
<tr>
<td>Elelyso, taliglucerase alfa</td>
<td>9/1/2018</td>
<td>dru002</td>
<td>Yes</td>
<td>J3060</td>
</tr>
<tr>
<td>Entyvio, vedolizumab</td>
<td>3/1/2015</td>
<td>dru444</td>
<td>Yes</td>
<td>J3380</td>
</tr>
<tr>
<td>Evenity, romosozumab</td>
<td>10/1/2019</td>
<td>dru594</td>
<td>Yes</td>
<td>J3590</td>
</tr>
<tr>
<td>Fabrazyme, agalsidase beta</td>
<td>7/1/2015</td>
<td>dru575</td>
<td>Yes</td>
<td>J0180</td>
</tr>
<tr>
<td>Inflectra, infliximab-dyyb</td>
<td>1/1/2017</td>
<td>dru444</td>
<td>Yes</td>
<td>Q5103</td>
</tr>
<tr>
<td>Immune globulin</td>
<td>3/1/2015</td>
<td>dru020</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Ixifi, infliximab-qbtex</td>
<td>10/1/2018</td>
<td>dru444</td>
<td>Yes</td>
<td>Q5109</td>
</tr>
<tr>
<td>Kanuma, sebelipase alfa</td>
<td>6/10/2016</td>
<td>dru426</td>
<td>Yes</td>
<td>J2840</td>
</tr>
<tr>
<td>Lumizyme, alglucosidase alfa</td>
<td>7/1/2015</td>
<td>dru426</td>
<td>Yes</td>
<td>J0221</td>
</tr>
<tr>
<td>Myozyme, alglucosidase alfa</td>
<td>7/1/2015</td>
<td>dru426</td>
<td>Yes</td>
<td>J0220</td>
</tr>
<tr>
<td>Naglazyme, galsulfase</td>
<td>4/1/2016</td>
<td>dru426</td>
<td>Yes</td>
<td>J1458</td>
</tr>
<tr>
<td>Ocrevus, ocrelizumab</td>
<td>9/1/2018</td>
<td>dru479</td>
<td>Yes</td>
<td>J2350</td>
</tr>
<tr>
<td>Onpattro, patisiran</td>
<td>4/1/2019</td>
<td>dru577</td>
<td>Yes</td>
<td>C9036</td>
</tr>
<tr>
<td>Orenicia, abatacept a</td>
<td>3/1/2015</td>
<td>dru444</td>
<td>Yes</td>
<td>J0129</td>
</tr>
<tr>
<td>Prolia, denosumab</td>
<td>7/1/2015</td>
<td>dru223</td>
<td>Yes</td>
<td>J0897</td>
</tr>
<tr>
<td>Radicava, edaravone</td>
<td>8/11/2017</td>
<td>dru510</td>
<td>Yes</td>
<td>J1301</td>
</tr>
<tr>
<td>Remicade, infliximab</td>
<td>3/1/2015</td>
<td>dru444</td>
<td>Yes</td>
<td>J1745</td>
</tr>
<tr>
<td>Renflelix, infliximab-abda</td>
<td>8/11/2017</td>
<td>dru444</td>
<td>Yes</td>
<td>Q5104</td>
</tr>
<tr>
<td>Revcovi, elapecogamessase</td>
<td>4/1/2019</td>
<td>dru426</td>
<td>Yes</td>
<td>J3590</td>
</tr>
<tr>
<td>Simponi Aria, golimumab a</td>
<td>3/1/2015</td>
<td>dru444</td>
<td>Yes</td>
<td>J1602</td>
</tr>
<tr>
<td>Soliris, eculizumab</td>
<td>5/1/2015</td>
<td>dru385</td>
<td>Yes</td>
<td>J1300</td>
</tr>
<tr>
<td>Trogarzo, ibalizumab-uiyk</td>
<td>6/1/2018</td>
<td>dru542</td>
<td>Yes</td>
<td>J1746</td>
</tr>
</tbody>
</table>

October 1, 2019

These criteria do not imply or guarantee approval. Please check with your plan to ensure coverage. Preauthorization requirements are only valid for the month published. They may have changed from previous months and may change in future months.
<table>
<thead>
<tr>
<th>Medication</th>
<th>Effective Date</th>
<th>Policy Number</th>
<th>Home infusion eligible b</th>
<th>HCPCS Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tysabri, natalizumab</td>
<td>5/1/2015</td>
<td>dru111</td>
<td>No</td>
<td>J2323</td>
</tr>
<tr>
<td>Ultomiris, ravulizumab</td>
<td>7/1/2019</td>
<td>dru385</td>
<td>Yes</td>
<td>J3590</td>
</tr>
<tr>
<td>Vimizim, elosulfase alfa</td>
<td>4/1/2016</td>
<td>dru426</td>
<td>Yes</td>
<td>J1322</td>
</tr>
<tr>
<td>VPRIV, velaglucerase alfa</td>
<td>4/1/2017</td>
<td>dru002</td>
<td>Yes</td>
<td>J3385</td>
</tr>
</tbody>
</table>

a This policy only applies to the formulations of these medications covered under the medical benefit. Formulations for self-administration may be available through the pharmacy benefit for most members.

b As of the date of the policy publication

---

### Appendix 2: Glossary

<table>
<thead>
<tr>
<th>Term</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approved site of care</td>
<td>Location where medications are safely and effectively administered by a health care professional. Approved sites of care include:</td>
</tr>
<tr>
<td></td>
<td>• Doctor’s offices</td>
</tr>
<tr>
<td></td>
<td>• Standalone ambulatory infusion centers</td>
</tr>
<tr>
<td></td>
<td>• Home infusion</td>
</tr>
<tr>
<td></td>
<td>• Approved hospital-based infusion centers</td>
</tr>
<tr>
<td>Unapproved site of care</td>
<td>Location where medications are administered by a professional and the facility is reimbursed for the medication and services at a much higher rate than approved sites of care. Unapproved sites of care include:</td>
</tr>
<tr>
<td></td>
<td>• Unapproved hospital-based infusion centers</td>
</tr>
</tbody>
</table>
### Appendix 3: Place of Service Codes and Descriptions

<table>
<thead>
<tr>
<th>Place of Service Code</th>
<th>Place of Service Name</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>Office</td>
<td>Location, other than a hospital, skilled nursing facility (SNF), military treatment facility, community health center, State or local public health clinic, or intermediate care facility (ICF), where the health professional routinely provides health examinations, diagnosis, and treatment of illness or injury on an ambulatory basis.</td>
</tr>
<tr>
<td>12</td>
<td>Home</td>
<td>Location, other than a hospital or other facility, where the patient receives care in a private residence.</td>
</tr>
<tr>
<td>19</td>
<td>Off Campus-Outpatient Hospital</td>
<td>A portion of an off-campus hospital provider based department which provides diagnostic, therapeutic (both surgical and nonsurgical), and rehabilitation services to sick or injured persons who do not require hospitalization or institutionalization.</td>
</tr>
<tr>
<td>22</td>
<td>On Campus-Outpatient Hospital</td>
<td>A portion of a hospital’s main campus which provides diagnostic, therapeutic (both surgical and nonsurgical), and rehabilitation services to sick or injured persons who do not require hospitalization or institutionalization.</td>
</tr>
</tbody>
</table>

### References

### Revision History

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Revision Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>7/24/2019</td>
<td>• Added Crysvita (burosumab) and Evenity (romosozumab) to the policy.</td>
</tr>
<tr>
<td>4/25/2019</td>
<td>• Added Revcovi (elapegademase) and Ultomiris (ravulizumab) to the policy.</td>
</tr>
</tbody>
</table>
| 1/31/2019       | • Added Onpattro (patisiran) to the policy, effective 4/1/2019.  
• Updated Appendix 1 HCPCS codes.                                                      |
| 8/17/2018       | • No criteria changes on this annual review.                                                                                                  |
| 6/15/2018       | • Clarify home infusion criteria I.B.1.b only applies to medications eligible for home infusion.  
• Updated Appendix 1, to include home infusion eligibility.                                |
| 5/18/2018       | • No change to intent of coverage criteria. Clarification of description, policy language, and addition of applicable J-codes. Defined approved and unapproved sites of care.  
• Added the following medications to the policy:  
  o Effective 6/1/2018: Trogarzo (ibalizumab-uiyk)  
  o Effective 9/1/2018: Elelyso (taliglucerase alfa), Ocrevus (ocrelizumab)  
  o Effective 10/1/2018: Ixifi (infliximab-qbtex)  
• Clarified medical exception criteria for concurrent cancer immunotherapy, including CAR T-cell therapy, and age less than 13 years old. |
| 8/11/2017       | Updated Appendix 1.                                                                                                                            |
| 1/17/2017       | Removed Lemtrada and Exondys from site of care program                                                                                         |
| 12/16/2016      | Updated Appendix 1.                                                                                                                            |
| 9/23/2016       | Updated Appendix 1.                                                                                                                            |
| 9/9/2016        | Select Utah plans are now included in the site of care review.                                                                                   |
| 7/15/2016       | Updated formatting of policy, added additional medical rationale for potential waivers to policy, noted distinction between approved and unapproved hospital outpatient settings, clarified affected members, and updated references. |

*Drug names identified in this policy are the trademarks of their respective owners.*
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E75.24</td>
<td>Niemann-Pick disease</td>
<td>G82.51</td>
<td>Quadriplegia, C1-C4 complete</td>
</tr>
<tr>
<td>E75.240</td>
<td>Niemann-Pick disease type A</td>
<td>G91.0</td>
<td>Communicating hydrocephalus</td>
</tr>
<tr>
<td>E75.241</td>
<td>Niemann-Pick disease type B</td>
<td>G91.1</td>
<td>Obstructive hydrocephalus</td>
</tr>
<tr>
<td>E75.242</td>
<td>Niemann-Pick disease type C</td>
<td>G91.3</td>
<td>Post-traumatic hydrocephalus, unspecified</td>
</tr>
<tr>
<td>E75.243</td>
<td>Niemann-Pick disease type D</td>
<td>G91.4</td>
<td>Hydrocephalus in diseases classified elsewhere</td>
</tr>
<tr>
<td>E75.248</td>
<td>Other Niemann-Pick disease</td>
<td>G91.8</td>
<td>Other hydrocephalus</td>
</tr>
<tr>
<td>E75.249</td>
<td>Niemann-Pick disease, unspecified</td>
<td>G91.9</td>
<td>Hydrocephalus, unspecified</td>
</tr>
<tr>
<td>E75.3</td>
<td>Sphingolipidosis, unspecified</td>
<td>G93.1</td>
<td>Anoxic brain damage, not elsewhere classified</td>
</tr>
<tr>
<td>E75.5</td>
<td>Other lipid storage disorders</td>
<td>G93.40</td>
<td>Encephalopathy, unspecified</td>
</tr>
<tr>
<td>E75.6</td>
<td>Lipid storage disorder, unspecified</td>
<td>G93.5</td>
<td>Compression of brain</td>
</tr>
<tr>
<td>E76</td>
<td>Disorders of glycosaminoglycan metabolism</td>
<td>G93.6</td>
<td>Cerebral edema</td>
</tr>
<tr>
<td>E76.0</td>
<td>Mucopolysaccharidosis, Type I</td>
<td>G93.7</td>
<td>Reye's syndrome</td>
</tr>
<tr>
<td>E76.01</td>
<td>Hurler's syndrome</td>
<td>G93.89</td>
<td>Other specified disorders of brain</td>
</tr>
<tr>
<td>E76.02</td>
<td>Hurler-Scheie syndrome</td>
<td>G93.9</td>
<td>Disorder of brain, unspecified</td>
</tr>
<tr>
<td>E76.03</td>
<td>Scheie's syndrome</td>
<td>G96.9</td>
<td>Disorder of central nervous system, unspecified</td>
</tr>
<tr>
<td>P07.30</td>
<td>Preterm newborn, unspecified weeks of gestation</td>
<td>G98.8</td>
<td>Other disorders of nervous system</td>
</tr>
<tr>
<td>P07.31</td>
<td>Preterm newborn, gestational age 28 completed weeks</td>
<td>P07.3</td>
<td>Preterm [premature] newborn [other]</td>
</tr>
<tr>
<td>P07.32</td>
<td>Preterm newborn, gestational age 29 completed weeks</td>
<td>P83.2</td>
<td>Hydrops fetalis not due to hemolytic disease</td>
</tr>
<tr>
<td>P07.33</td>
<td>Preterm newborn, gestational age 30 completed weeks</td>
<td>Q01.0</td>
<td>Feeding problems of newborn</td>
</tr>
<tr>
<td>P07.34</td>
<td>Preterm newborn, gestational age 31 completed weeks</td>
<td>Q01.1</td>
<td>Frontal encephalocele</td>
</tr>
<tr>
<td>P07.35</td>
<td>Preterm newborn, gestational age 32 completed weeks</td>
<td>Q01.2</td>
<td>Nasofrontal encephalocele</td>
</tr>
</tbody>
</table>

These criteria do not imply or guarantee approval. Please check with your plan to ensure coverage. Preauthorization requirements are only valid for the month published. They may have changed from previous months and may change in future months.
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>P07.36</td>
<td>Preterm newborn, gestational age 33 completed weeks</td>
<td>Q01.8</td>
<td>Occipital encephalocele</td>
</tr>
<tr>
<td>P07.37</td>
<td>Preterm newborn, gestational age 34 completed weeks</td>
<td>Q01.9</td>
<td>Encephalocele of other sites</td>
</tr>
<tr>
<td>P07.38</td>
<td>Preterm newborn, gestational age 35 completed weeks</td>
<td>Q02</td>
<td>Encephalocele, unspecified</td>
</tr>
<tr>
<td>P07.39</td>
<td>Preterm newborn, gestational age 36 completed weeks</td>
<td>Q03.0</td>
<td>Microcephaly</td>
</tr>
<tr>
<td>Q06</td>
<td>Other congenital malformations of spinal cord</td>
<td>Q03.1</td>
<td>Malformations of aqueduct of Sylvius</td>
</tr>
<tr>
<td>Q06.0</td>
<td>Amyelia</td>
<td>Q03.8</td>
<td>Atresia of foramina of Magendie and Luschka</td>
</tr>
<tr>
<td>Q06.1</td>
<td>Hypoplasia and dysplasia of spinal cord</td>
<td>Q03.9</td>
<td>Other congenital hydrocephalus</td>
</tr>
<tr>
<td>Q06.2</td>
<td>Diastematomyelia</td>
<td>Q04.0</td>
<td>Congenital hydrocephalus, unspecified</td>
</tr>
<tr>
<td>Q06.3</td>
<td>Other congenital cauda equina malformations</td>
<td>Q04.1</td>
<td>Arhinencephaly</td>
</tr>
<tr>
<td>Q06.4</td>
<td>Hydromyelia</td>
<td>Q04.2</td>
<td>Holoprosencephaly</td>
</tr>
<tr>
<td>Q06.8</td>
<td>Other specified congenital malformations of spinal cord</td>
<td>Q04.3</td>
<td>Other reduction deformities of brain</td>
</tr>
<tr>
<td>Q92.6</td>
<td>Marker chromosomes</td>
<td>Q04.4</td>
<td>Septo-optic dysplasia of brain</td>
</tr>
<tr>
<td>Q93</td>
<td>Monosomies and deletions from the autosomes, not elsewhere classified</td>
<td>Q04.5</td>
<td>Megalencephaly</td>
</tr>
<tr>
<td>Q93.51</td>
<td>Angelman syndrome</td>
<td>Q04.6</td>
<td>Congenital cerebral cysts</td>
</tr>
<tr>
<td>Q93.59</td>
<td>Other deletions of part of a chromosome</td>
<td>Q04.8</td>
<td>Other specified congenital malformations of brain</td>
</tr>
<tr>
<td>Q93.8</td>
<td>Other deletions from the autosomes</td>
<td>Q04.9</td>
<td>Congenital malformation of brain, unspecified</td>
</tr>
<tr>
<td>Q93.82</td>
<td>Williams syndrome</td>
<td>Q05.0</td>
<td>Cervical spina bifida with hydrocephalus</td>
</tr>
<tr>
<td>D82.1</td>
<td>Di George's syndrome</td>
<td>Q05.1</td>
<td>Thoracic spina bifida with hydrocephalus</td>
</tr>
<tr>
<td>E75.0</td>
<td>GM2 gangliosidosis</td>
<td>Q05.2</td>
<td>Lumbar spina bifida with hydrocephalus</td>
</tr>
<tr>
<td>E75.00</td>
<td>GM2 gangliosidosis, unspecified</td>
<td>Q05.3</td>
<td>Sacral spina bifida with hydrocephalus</td>
</tr>
<tr>
<td>Code</td>
<td>Condition</td>
<td>Code</td>
<td>Condition</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------</td>
<td>--------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>E75.01</td>
<td>Sandhoff disease</td>
<td>Q05.4</td>
<td>Unspecified spina bifida with hydrocephalus</td>
</tr>
<tr>
<td>E75.02</td>
<td>Tay-Sachs disease</td>
<td>Q05.5</td>
<td>Cervical spina bifida without hydrocephalus</td>
</tr>
<tr>
<td>E75.09</td>
<td>Other GM2 gangliosidosis</td>
<td>Q05.6</td>
<td>Thoracic spina bifida without hydrocephalus</td>
</tr>
<tr>
<td>E75.1</td>
<td>Other and unspecified gangliosidosis</td>
<td>Q05.7</td>
<td>Lumbar spina bifida without hydrocephalus</td>
</tr>
<tr>
<td>E75.10</td>
<td>Unspecified gangliosidosis</td>
<td>Q05.8</td>
<td>Sacral spina bifida without hydrocephalus</td>
</tr>
<tr>
<td>E75.11</td>
<td>Mucolipidosis IV</td>
<td>Q05.9</td>
<td>Spina bifida, unspecified</td>
</tr>
<tr>
<td>E75.19</td>
<td>Other gangliosidosis</td>
<td>Q06.9</td>
<td>Congenital malformation of spinal cord, unspecified</td>
</tr>
<tr>
<td>E75.2</td>
<td>Other sphingolipidosis</td>
<td>Q07.00</td>
<td>Arnold-Chiari syndrome without spina bifida or hydrocephalus</td>
</tr>
<tr>
<td>E75.21</td>
<td>Fabry (-Anderson) disease</td>
<td>Q07.01</td>
<td>Arnold-Chiari syndrome with spina bifida</td>
</tr>
<tr>
<td>E75.22</td>
<td>Gaucher disease</td>
<td>Q07.02</td>
<td>Arnold-Chiari syndrome with hydrocephalus</td>
</tr>
<tr>
<td>E75.23</td>
<td>Krabbe disease</td>
<td>Q07.03</td>
<td>Arnold-Chiari syndrome with spina bifida and hydrocephalus</td>
</tr>
<tr>
<td>E75.25</td>
<td>Metachromatic leukodystrophy</td>
<td>Q07.8</td>
<td>Other specified congenital malformation of nervous system</td>
</tr>
<tr>
<td>E75.26</td>
<td>Sulfatase deficiency</td>
<td>Q07.9</td>
<td>Congenital malformation of nervous system, unspecified</td>
</tr>
<tr>
<td>E75.29</td>
<td>Other sphingolipidosis</td>
<td>Q90.0</td>
<td>Trisomy 21, nonmosaicism (meiotic nondisjunction)</td>
</tr>
<tr>
<td>E75.4</td>
<td>Neuronal ceroid lipofuscinosis</td>
<td>Q90.1</td>
<td>Trisomy 21, mosaicism (mitotic nondisjunction)</td>
</tr>
<tr>
<td>E78.71</td>
<td>Barth syndrome</td>
<td>Q90.2</td>
<td>Trisomy 21, translocation</td>
</tr>
<tr>
<td>E78.72</td>
<td>Smith-Lemli-Opitz syndrome</td>
<td>Q90.9</td>
<td>Down syndrome, unspecified</td>
</tr>
<tr>
<td>F70</td>
<td>Mild intellectual disabilities</td>
<td>Q91.0</td>
<td>Trisomy 18, nonmosaicism (meiotic nondisjunction)</td>
</tr>
<tr>
<td>F71</td>
<td>Moderate intellectual disabilities</td>
<td>Q91.1</td>
<td>Trisomy 18, mosaicism (mitotic nondisjunction)</td>
</tr>
<tr>
<td>F72</td>
<td>Severe intellectual disabilities</td>
<td>Q91.2</td>
<td>Trisomy 18, translocation</td>
</tr>
<tr>
<td>F73</td>
<td>Profound intellectual disabilities</td>
<td>Q91.3</td>
<td>Trisomy 18, unspecified</td>
</tr>
<tr>
<td>F78</td>
<td>Other intellectual disabilities</td>
<td>Q91.4</td>
<td>Trisomy 13, nonmosaicism (meiotic nondisjunction)</td>
</tr>
<tr>
<td>F79</td>
<td>Unspecified intellectual disabilities</td>
<td>Q91.5</td>
<td>Trisomy 13, mosaicism (mitotic nondisjunction)</td>
</tr>
<tr>
<td>F82</td>
<td>Specific developmental disorder of motor</td>
<td>Q91.6</td>
<td>Trisomy 13, translocation</td>
</tr>
<tr>
<td>Code</td>
<td>Diagnosis</td>
<td>Additional Information</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>---------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>F84</td>
<td>Pervasive developmental disorders</td>
<td>Q91.7 Trisomy 13, unspecified</td>
<td></td>
</tr>
<tr>
<td>F84.0</td>
<td>Autistic disorder</td>
<td>Q92.0 Whole chromosome trisomy, nonmosaicism (meiotic nondisjunction)</td>
<td></td>
</tr>
<tr>
<td>F84.2</td>
<td>Rett's syndrome</td>
<td>Q92.1 Whole chromosome trisomy, mosaicism (mitotic nondisjunction)</td>
<td></td>
</tr>
<tr>
<td>F84.3</td>
<td>Other childhood disintegrative disorder</td>
<td>Q92.2 Partial trisomy</td>
<td></td>
</tr>
<tr>
<td>F84.5</td>
<td>Asperger's syndrome</td>
<td>Q92.5 Duplications with other complex rearrangements</td>
<td></td>
</tr>
<tr>
<td>F84.8</td>
<td>Other pervasive developmental disorders</td>
<td>Q92.61 Marker chromosomes in normal individual</td>
<td></td>
</tr>
<tr>
<td>F84.9</td>
<td>Pervasive developmental disorder, unspecified</td>
<td>Q92.62 Marker chromosomes in abnormal individual</td>
<td></td>
</tr>
<tr>
<td>F88</td>
<td>Other disorders of psychological development</td>
<td>Q92.7 Triploidy and polyploidy</td>
<td></td>
</tr>
<tr>
<td>F89</td>
<td>Unspecified disorder of psychological development</td>
<td>Q92.8 Other specified trisomies and partial trisomies of autosomes</td>
<td></td>
</tr>
<tr>
<td>F90</td>
<td>Attention-deficit hyperactivity disorders</td>
<td>Q92.9 Trisomy and partial trisomy of autosomes, unspecified</td>
<td></td>
</tr>
<tr>
<td>F98.2</td>
<td>Other feeding disorders of infancy and childhood</td>
<td>Q93.0 Whole chromosome monosomy, nonmosaicism (meiotic nondisjunction)</td>
<td></td>
</tr>
<tr>
<td>F98.9</td>
<td>Unspecified behavioral and emotional disorders with onset usually occurring in childhood and adolescence</td>
<td>Q93.1 Whole chromosome monosomy, mosaicism (mitotic nondisjunction)</td>
<td></td>
</tr>
<tr>
<td>G11.1</td>
<td>Early-onset cerebellar ataxia</td>
<td>Q93.2 Chromosome replaced with ring, dicentric or isochromosome</td>
<td></td>
</tr>
<tr>
<td>G12.0</td>
<td>Infantile spinal muscular atrophy, type I [Werdnig-Hoffman]</td>
<td>Q93.3 Deletion of short arm of chromosome 4</td>
<td></td>
</tr>
<tr>
<td>G12.1</td>
<td>Other inherited spinal muscular atrophy</td>
<td>Q93.4 Deletion of short arm of chromosome 5</td>
<td></td>
</tr>
<tr>
<td>G31.84</td>
<td>Mild cognitive impairment, so stated</td>
<td>Q93.5 Other deletions of part of a chromosome</td>
<td></td>
</tr>
<tr>
<td>G71.0</td>
<td>Muscular Dystrophy</td>
<td>Q93.7 Deletions with other complex rearrangements</td>
<td></td>
</tr>
<tr>
<td>G71.00</td>
<td>Muscular dystrophy, unspecified</td>
<td>Q93.81 Velo-cardio-facial syndrome</td>
<td></td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------------------------</td>
<td>----------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>G71.01</td>
<td>Duchenne or Becker muscular dystrophy</td>
<td>Q93.88</td>
<td>Other microdeletions</td>
</tr>
<tr>
<td>G71.02</td>
<td>Facioscapulohumeral muscular dystrophy</td>
<td>Q93.89</td>
<td>Other deletions from the autosomes</td>
</tr>
<tr>
<td>G71.09</td>
<td>Other specified muscular dystrophies</td>
<td>Q93.9</td>
<td>Deletion from autosomes, unspecified</td>
</tr>
<tr>
<td>G71.11</td>
<td>Myotonic muscular dystrophy</td>
<td>Q95.2</td>
<td>Balanced autosomal rearrangement in abnormal individual</td>
</tr>
<tr>
<td>G71.12</td>
<td>Myotonia congenita</td>
<td>Q95.3</td>
<td>Balanced sex/autosomal rearrangement in abnormal individual</td>
</tr>
<tr>
<td>G71.13</td>
<td>Myotonic chondrodystrophy</td>
<td>Q99.2</td>
<td>Fragile X chromosome</td>
</tr>
<tr>
<td>G71.14</td>
<td>Drug induced myotonia</td>
<td>Q99.8</td>
<td>Other specified chromosome abnormalities</td>
</tr>
<tr>
<td>G71.19</td>
<td>Other specified myotonic disorders</td>
<td>Q99.9</td>
<td>Chromosomal abnormality, unspecified</td>
</tr>
<tr>
<td>G71.2</td>
<td>Congenital myopathies</td>
<td>R27.9</td>
<td>Unspecified lack of coordination</td>
</tr>
<tr>
<td>G80.0</td>
<td>Spastic quadriplegic cerebral palsy</td>
<td>R62.0</td>
<td>Delayed milestone in childhood</td>
</tr>
<tr>
<td>G80.1</td>
<td>Spastic diplegic cerebral palsy</td>
<td>R62.50</td>
<td>Unspecified lack of expected normal physiological development in childhood</td>
</tr>
<tr>
<td>G80.2</td>
<td>Spastic hemiplegic cerebral palsy</td>
<td>R62.51</td>
<td>Failure to thrive (child)</td>
</tr>
<tr>
<td>G80.3</td>
<td>Athetoid cerebral palsy</td>
<td>R62.59</td>
<td>Other lack of expected normal physiological development in childhood</td>
</tr>
<tr>
<td>G80.4</td>
<td>Ataxic cerebral palsy</td>
<td>R63.3</td>
<td>Feeding difficulties</td>
</tr>
<tr>
<td>G80.8</td>
<td>Other cerebral palsy</td>
<td>T74.4XXA</td>
<td>Shaken infant syndrome, initial encounter</td>
</tr>
<tr>
<td>G80.9</td>
<td>Cerebral palsy, unspecified</td>
<td>T74.4XXD</td>
<td>Shaken infant syndrome, subsequent encounter</td>
</tr>
<tr>
<td></td>
<td></td>
<td>T74.4XXS</td>
<td>Shaken infant syndrome, sequela</td>
</tr>
</tbody>
</table>